All conditions

Pancreatic Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

2869
Trials on record
544
Recruiting now
23
Australian sites
46
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Pancreatic Cancer →

Get alerts when Pancreatic Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Pancreatic Cancer

Pancreatic cancer is a disease where abnormal cells grow in the pancreas, a gland sitting deep in the abdomen behind the stomach. The pancreas has two important jobs: it helps digest food by making enzymes, and it controls blood sugar by producing hormones like insulin. Cancer can develop in different parts of the pancreas, though the most common type starts in the cells that line the ducts carrying digestive juices. Because the pancreas sits so deep in the body, and because the disease often causes no obvious symptoms in its early stages, it is frequently diagnosed at a later stage when it has already spread.

In Australia, around 4,000 people are diagnosed with pancreatic cancer each year, making it one of the more serious cancer diagnoses a person can receive. It can affect people of any background, though it is more commonly diagnosed in people over 60. Certain factors such as smoking, long-term diabetes, chronic pancreatitis, and family history can increase a person's risk, though many people diagnosed have none of these factors.

Treatment depends on several things, including where the cancer is located, whether it has spread, and a person's overall health. Options that doctors may discuss include surgery to remove the tumour where possible, chemotherapy, radiation therapy, or combinations of these approaches. Some people may also be offered participation in clinical trials testing newer treatments. A team of specialists — often including surgeons, oncologists, and specialist nurses — will typically work together to guide care. Palliative care, which focuses on managing symptoms and maintaining comfort, may also be part of the care plan at any stage of the disease.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Pancreatic Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Pancreatic Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Pancreatic Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Pancreatic Cancer by country. Australia is highlighted.

Showing the top 10 of 50 countries with trial sites.

Clinical trials for Pancreatic Cancer

Showing 552 of 552 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00844649 · Celgene Phase 3 · 11 countries Completed
Completed Phase 3 Est. completion 17 September 2012
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇷🇺 RU +3 more

**Who might be able to join this trial:** - You have been diagnosed with pancreatic cancer (specifically adenocarcinoma) that has spread to other parts of the body (metastatic), confirmed by a tissue or cell sample - Your diagnosis of metastatic disease was made no more than 6 weeks before joining the study - At least...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01231347 · NantCell, Inc. Phase 3 · 32 countries Completed
Completed Phase 3 Est. completion 12 December 2012
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇩🇰 DK +24 more

Who might be able to join this trial: - You have been diagnosed with pancreatic cancer (specifically adenocarcinoma) that has spread to other parts of the body and has not yet been treated. - Your blood counts, kidneys, and liver are working well enough to meet the trial's health requirements. - You are generally able...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04429542 · Bicara Therapeutics Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have a tumour that can be measured, that is accessible for a biopsy, and who are willing to have two biopsies (one before treatment and one during treatment), and can provide stored tumour tissue if it is available. - People who are generally well enough to carry...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04924075 · Merck Sharp & Dohme LLC Phase 2 · 22 countries Recruiting
Recruiting Phase 2 Est. completion 27 December 2029
🇦🇺 AU🇨🇦 CA🇨🇱 CL🇨🇳 CN🇩🇰 DK🇫🇷 FR🇩🇪 DE🇭🇺 HU +14 more

Who might be able to join this trial: - People who are at least 12 years old (or at least 18 years old for a specific group called Cohort B1) - People who have been diagnosed with one of the following: advanced or metastatic pheochromocytoma/paraganglioma (tumours of the adrenal gland or nearby nerve tissue), pancreati...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04970056 · Arbor Research Collaborative for Health Not Applicable · 11 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇦🇺 AU🇨🇦 CA🇭🇺 HU Iceland🇮🇱 IL🇮🇹 IT🇸🇬 SG🇪🇸 ES +3 more

**Who might be able to join this trial:** This trial involves a registry called PRECEDE for people being assessed for pancreatic cancer (PDAC) risk. There are several groups that may be eligible: - People with no personal history of pancreatic cancer who have two or more relatives with pancreatic cancer on the same s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05141149 · Prestige Biopharma Limited Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 February 2026
🇦🇺 AU🇸🇬 SG🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older (or the legal age of majority in the country where the trial is being run) at the time of giving consent. - People who are willing and able to understand, sign, and date a written consent form before any trial procedures begin. - People with a general...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05254171 · Panbela Therapeutics, Inc. Phase 3 · 10 countries Recruiting
Recruiting Phase 3 Est. completion 29 August 2026
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇰🇷 KR🇪🇸 ES +2 more

**Who might be able to join this trial:** - People who have been diagnosed with metastatic pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer that has spread), confirmed by a tissue or cell sample. - People who have not yet received treatment for their metastatic disease, whose metastatic diagnosis...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05417594 · AstraZeneca Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇦🇺 AU🇩🇪 DE🇰🇷 KR🇪🇸 ES🇸🇪 SE🇬🇧 GB🇺🇸 US

Who might be able to join this trial: **General requirements (all modules):** - People whose cancer is currently progressing at the time of enrolment - People who are well enough to carry out daily activities, with no worsening in the two weeks before enrolment (as measured by a standard performance scale) - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06179160 · Incyte Corporation Phase 1 · 8 countries Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇮🇹 IT🇯🇵 JP🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older. - People who have a locally advanced or spreading solid tumour cancer that has a specific genetic change called a KRAS G12D mutation. - For certain parts of the trial: People whose cancer has continued to grow despite previous standard tre...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06244771 · Frontier Medicines Corporation Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇦🇺 AU🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed solid tumour (by lab testing of tissue or cells) that has spread or cannot be surgically removed, and whose tumour has a specific genetic change called a KRAS G12C mutation - People whose cancer has continued to grow during or after standard treat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06319755 · Royal Prince Alfred Hospital, Sydney, Australia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇦🇺 AU

**Who might be able to join this trial:** - Adults aged 18 or older who had a type of major surgery called a Whipple's procedure (removal of part of the pancreas and surrounding structures) between April 2018 and December 2023, with the goal of curing their condition, and who received their post-surgery care at Royal P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06345079 · Australasian Gastro-Intestinal Trials Group Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇦🇺 AU🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 or older who have a well or moderately differentiated neuroendocrine tumour (NET) of the mid-gut, hind-gut, or pancreas that has spread to other parts of the body and cannot be removed by surgery, and whose tumour has continued to grow despite receiving a soma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06428409 · Merck Sharp & Dohme LLC Phase 2 · 13 countries Recruiting
Recruiting Phase 2 Est. completion 16 October 2029
🇦🇺 AU🇨🇦 CA🇨🇱 CL🇨🇳 CN🇮🇹 IT🇯🇵 JP🇰🇷 KR🇪🇸 ES +5 more

**Who might be able to join this trial:** - You have colorectal cancer that cannot be removed by surgery or has spread to other parts of the body, and you have already received at least one previous cancer treatment - You have advanced or metastatic pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06885034 · GlaxoSmithKline Phase 2 · 19 countries Recruiting
Recruiting Phase 2 Est. completion 10 January 2028
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇫🇮 FI🇫🇷 FR🇩🇪 DE🇮🇹 IT +11 more

**Who might be able to join this trial:** **For the colorectal cancer group:** - Adults aged 18 or older (or the legal age of consent in the country where the trial is taking place) - People with a confirmed diagnosis of advanced colon or rectal cancer that cannot be surgically removed, either because it has spread lo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06907043 · Eikon Therapeutics Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇦🇺 AU🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People with breast cancer who have received at least one prior chemotherapy treatment (either before surgery, after surgery, or for advanced/spread disease), and hormone therapy if their cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06914128 · Bayer Phase 2 · 13 countries Recruiting
Recruiting Phase 2 Est. completion 17 June 2029
🇦🇺 AU🇧🇪 BE🇨🇳 CN🇨🇿 CZ🇩🇰 DK🇮🇹 IT🇯🇵 JP🇳🇱 NL +5 more

**Who might be able to join this trial:** - People who are 18 years of age or older (or the legal age of consent in the country where the study takes place) at the time of signing the consent form. - People who have at least one tumour that can be measured using standard imaging criteria (known as RECIST 1.1). - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06917079 · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of advanced cancer (non-small cell lung cancer, pancreatic cancer, colorectal cancer, or another solid tumor) that has spread or cannot be surgically removed, and your tumor has been confirmed by a lab test to have a specific gene...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06943755 · Exelixis Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2029
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT +7 more

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by laboratory tissue testing) with a neuroendocrine tumour (NET) that started in the pancreas or another part of the body, and the tumour is either advanced, cannot be surgically removed, or has spread to other parts of the body, and...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06989437 · Pfizer Phase 3 · 21 countries Recruiting
Recruiting Phase 3 Est. completion 17 January 2028
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE +13 more

**Who might be able to join this trial:** - You have signed a consent form agreeing to take part in the study - You have been diagnosed with pancreatic cancer that has spread to other parts of the body (specifically a type called pancreatic ductal adenocarcinoma) - You have been experiencing significant unintentional w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07020221 · Verastem, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇦🇺 AU🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older. - You must be willing and able to sign a consent form approved by an ethics review board. - You must have a solid tumor (cancer) that has been confirmed by lab testing to have a specific genetic change called a KRAS G12D mutation, and the can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07072728 · Psyence Australia Pty Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who have been assessed and found to have an adjustment disorder (a stress-related condition) based on specific questionnaire scores, including a distress score of 4 or higher on a standard scale. - People whose anxiety has been measured as moderate or higher on a stan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07094113 · Amgen Phase 1 · 14 countries Recruiting
Recruiting Phase 1 Est. completion 18 April 2028
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT +6 more

**Who might be able to join this trial:** - You must be 18 years of age or older (or meet the legal adult age in your country, if that is older than 18). - You have been diagnosed with an advanced or spread-out cancer that has a specific type of gene change (called a "missense mutation") or extra copies of a gene call...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07229313 · Kivu Bioscience Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 31 March 2028
🇦🇺 AU🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People whose cancer type has no currently available treatment known to be effective - People who have been formally diagnosed (through tissue or cell testing) with an advanced or spreading solid tumour cancer that has stopped responding to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07562152 · Immuneering Corporation Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with metastatic pancreatic adenocarcinoma (a specific type of pancreatic cancer that has spread to other parts of the body), confirmed within the last 12 weeks before screening - People whose general physical hea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07644559 · Verastem, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by laboratory testing of tissue samples - People who have at least one area of cancer that can be measured on a scan, according to a standard set of measure...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01020006 · Pharmacyclics LLC. Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 August 2012
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older with a body weight between 40 kg and 100 kg. - People who have been diagnosed with a specific type of pancreatic cancer called ductal adenocarcinoma that has spread to other parts of the body (metastatic), diagnosed within the past 4 months (Part A) or wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02651987 · Ipsen Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 16 October 2019
🇧🇪 BE🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇹 IT🇳🇱 NL🇵🇱 PL +2 more

**Who might be able to join this trial:** - You have been diagnosed with a neuroendocrine tumour (NET) of the pancreas or the middle part of the small intestine (midgut), confirmed by a tissue sample, that is either grade 1 or grade 2, and has spread to other parts of the body or cannot be removed by surgery. - Your tu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02704143 · Changhai Hospital Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 1 May 2020
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with locally advanced pancreatic cancer, confirmed by a CT or MRI scan and a tissue biopsy - You have not received any treatment for your pancreatic cancer before the radiation treatment used in this trial (called SBRT) - Your doctors expect you to li...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06774170 · Dokuz Eylul University Not Applicable · 1 country By Invitation
By Invitation Not Applicable Est. completion 1 November 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - You are 18 years of age or older - You own and use a smartphone that works with the Dexcom G6 app - You have access to the internet - You scored above a certain level on a short memory and thinking test (the exact score required depends on your level of education — confirm wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05010226 · National Taiwan University Hospital Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 July 2022

**Who might be able to join this trial:** - You are 20 years old or older - You are willing and able to sign and date a consent form agreeing to take part - You are willing to follow all the steps of the registry and are available for the full duration of the study - You have been diagnosed with pancreatic cancer (conf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05802485 · Institut Paoli-Calmettes Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 February 2029

**Who might be able to join this trial:** - You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that has not spread to other parts of the body, and cannot be removed by surgery straight away (classified as "borderline" or "locally advanced") - You have not yet had any surgery or chemo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00001276 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

"Who might be able to join this trial: - You must be 18 years of age or older (male or female). - You must have a documented fasting blood sugar level below 55 mg/dl (measured after not eating for a period of time). - You must have lab test results suggesting an insulinoma (a type of tumor on the pancreas) or another t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00027274 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following inherited bone marrow failure conditions: Fanconi anemia, Diamond Blackfan anemia, Dyskeratosis congenita, Shwachman Diamond Syndrome, Amegakaryocytic thrombocytopenia, Thrombocytopenia absent radii, Severe Congenital Neutrop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00912717 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic adenocarcinoma (a type of pancreatic cancer), either confirmed by tissue sample or by a CT scan - People who have an abnormal result on an imaging scan of the pancreas area (such as a CT, MRI, or similar scan) - People who have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01102556 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with pancreatic cancer, are suspected of having pancreatic cancer, or have a pre-cancerous growth in the pancreas - Adults aged 18 or older who have had two or more cancers linked to a condition called hereditary nonpolyposis c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01365169 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with stage I–IV colorectal cancer, or colorectal cancer that has come back (Arm 1) - People who can speak, read, and write in English (Pre-pilot phase, Arms 1–4) - People who are able to give informed consent to participate (Pre-pilot phase, Arms 1–4, PCS st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01885299 · The Radiosurgery Society Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a benign (non-cancerous) or malignant (cancerous) tumor, or another condition that your doctor believes can be treated with a highly targeted type of radiation therapy (called stereotactic radiosurgery or stereotactic body radiotherapy). - You are wil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02021604 · Cook Children's Health Care System Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with Hyperinsulinism (HI) who are receiving care at the Cook Children's Congenital Hyperinsulinism Center and are being treated by an Endocrinologist connected to the trial. - People whose Endocrinologist has determined that standard medications have not wor...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02361320 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 June 2028
🇺🇸 US

**Who might be able to join this trial:** **For pancreatic cancer patients:** - You have been diagnosed with pancreatic cancer that has been confirmed by a tissue sample (biopsy) - Your cancer has not spread to distant parts of the body, but is either too complex to remove with surgery right away ("locally advanced")...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02393703 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older and are scheduled to have surgery to remove part or all of your pancreas, or a nearby structure called the duodenum, for a suspected pancreatic condition - Your condition is one of the following: a type of pancreatic cancer (ductal adenocarcin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02478892 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have a confirmed inherited gene mutation in one of the following genes: BRCA1, BRCA2, ATM, or PALB2 - People with no close family history of pancreatic cancer (no parent, sibling, child, grandparent, aunt, uncle, niece, or neph...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02598349 · Proton Collaborative Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2039
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that cannot be removed by surgery, confirmed by a biopsy. - Your cancer is either too difficult to remove surgically, you have health reasons that make surgery unsafe, or you have chosen not to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02674100 · University of Louisville Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇨🇦 CA🇯🇵 JP🇲🇽 MX🇹🇼 TW🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - Adults (over 18 years old) who have been diagnosed with pancreatic cancer and whose treating doctor has determined they are suitable for a soft tissue ablation procedure. Who may not be able to join: - People who have a cardiac pacemaker or an implanted heart defibrillator (ICD)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02843945 · CivaTech Oncology Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have signed a consent form agreeing to take part in the study - You are not currently pregnant or breastfeeding - You are healthy enough to safely receive anesthesia (sedation for surgery) - You are scheduled to have one of two specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02869581 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with a pancreatic neoplasm (a tumour or abnormal growth on the pancreas) Who may not be able to join: - People who have been diagnosed with cholangiocarcinoma (a type of cancer that forms in the bile ducts) Important: Always verify eligibility wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02869802 · British Columbia Cancer Agency Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) that has spread to other parts of the body, confirmed by tissue sample and/or imaging scans — those without a tissue-confirmed diagnosis must have a biopsy done before starting...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02871336 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2030
🇫🇷 FR

"Who might be able to join this trial: - Adults over 18 years old - People who are having surgery for pancreatic cancer Who may not be able to join: - People who do not wish to take part in the study Important: Always verify eligibility with the trial site directly before applying."

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03048266 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇺🇸 US

**Who might be able to join this trial:** - You have been confirmed to have a condition called MEN1 (Multiple Endocrine Neoplasia type 1), whether this was diagnosed through clinical assessment, a genetic test, or because it runs in your family. - You have never previously been diagnosed with a pancreatic neuroendocrin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03218345 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
Hong Kong

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a type of pancreatic tumor (either a pancreatic neuroendocrine tumor or pancreatic ductal carcinoma) that is smaller than 5cm and was confirmed by a specific type of biopsy using a fine needle - You are not suitable for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03250078 · Nuvance Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have at least 2 close family members (parents, siblings, or children) who have had pancreatic cancer. - People who have at least 3 family members across multiple generations who have had pancreatic cancer, with at least one of those being a close family member (pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03257033 · RenovoRx Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇧🇪 BE🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed through a tissue or cell sample, with diagnosis made within 8 weeks of signing consent (or, for those joining at the second treatment cycle, from the start of that...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03311776 · Inna Chen, MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 July 2035
🇩🇰 DK

Who might be able to join this trial: - You must be over 18 years old - You have been diagnosed with pancreatic cancer (specifically a type called ductal adenocarcinoma) or a cancer near the opening of the small intestine (called ampullary adenocarcinoma), confirmed by examining tissue from surgery; OR you have had can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03454035 · UNC Lineberger Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older (there is no upper age limit) - You have given written permission to take part and for your health information to be used - You are generally able to care for yourself and carry out some daily activities, even if you cannot do heavy physical...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03492151 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been referred for a specific type of ultrasound-guided biopsy procedure (called EUS-FNA) to examine a fluid-filled sac (cyst) on your pancreas, and surgery is being considered - Your pancreatic cyst measures at least 2.0 cm (about t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03492671 · Loma Linda University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been confirmed by a lab test (from a tissue or fluid sample) to have a type of pancreatic cancer called adenocarcinoma. - Your cancer is located only in the pancreas and may be removable by surgery. - You are 18 years of age or older. - You are generally healthy and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03498326 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2023
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older - People who have had surgery that completely removed the cancer with no cancer cells left at the edges (called R0 resection) - People who have not previously been treated with a chemotherapy drug called gemcitabine for any cancer - People who a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03536793 · Hull University Teaching Hospitals NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older who are able to give written consent to participate - People diagnosed with localised pancreatic cancer where surgery (such as removal of part or all of the pancreas) is possible - People diagnosed with localised pancreatic cancer that cannot be opera...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03579836 · BeyondBio Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2026
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas, confirmed through a tissue or cell sample - People who have at least one tumour that can be measured using standard imaging guidelines (RECIST v1.1) - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03582189 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇨🇦 CA

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with advanced pancreatic cancer or liver cancer (hepatocellular carcinoma) that has not spread far beyond its original location, and your doctors are considering treating it with a combination of chemotherapy and radiation,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03637569 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇰🇷 KR

Who might be able to join this trial: - People who have been newly diagnosed with pancreatic cancer, bile duct cancer, or gallbladder cancer and are currently receiving some form of treatment, such as surgery, chemotherapy, or palliative care. - People who are 18 years of age or older. Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03652428 · University of Maryland, Baltimore Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed by a lab test on tissue or fluid samples. - People whose cancer has not spread to distant parts of the body (no metastatic disease). - People whose scans clearly s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03711890 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2026
🇺🇸 US

Who might be able to join this trial: - Adults who have been diagnosed with pancreatic cancer or a type of pancreatic cyst called IPMN (Intraductal Papillary Mucinous Neoplasm) and are scheduled for surgery soon - Adults who are having surgery to remove part of the pancreas because of a suspected IPMN - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03747588 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2023
🇨🇳 CN

Who might be able to join this trial: - Adults aged between 18 and 75 years old - People who have been diagnosed with pancreatic cancer, bile duct cancer, or cancer of the ampulla (a small opening where the bile and pancreatic ducts meet the small intestine), and who have had a surgical procedure called a pancreatoduod...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03785743 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer), either confirmed through a tissue sample or diagnosed by a specialist medical team without a tissue sample - People whose medical team...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03791073 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2019
🇫🇷 FR

Who might be able to join this trial: - People who have a mass in the pancreas and a suspected diagnosis of pancreatic ductal adenocarcinoma (a type of pancreatic cancer) that requires either an endoscopic ultrasound with a needle biopsy or surgery - People who are 18 years of age or older - People who have not yet rec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03855800 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2030
🇺🇸 US

Who might be able to join this trial: - People who have fluid-filled sacs (cysts) in the pancreas that meet specific concern levels known as "Fukuoka worrisome" or "Fukuoka high-risk" criteria (confirm with trial site for what this means in your case) - People who are suspected to have a type of cyst in the pancreas th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03915678 · Institut Bergonié Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with one of the following cancer types, confirmed by laboratory tissue testing: pancreatic cancer, certain virus-linked cancers (such as cervical, head and neck, nasal, or nasopharyngeal cancers), Kaposi's sarcoma, non-small cell lung cancer, s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03937453 · Nuvance Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 50 years old. - People diagnosed with diabetes within the past 12 months, where there is a record of previously normal blood sugar levels within the past 2 years, and whose HbA1c (a blood sugar level measure) is 6.5% or above. - People diagnosed with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03977233 · UNC Lineberger Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have signed a written consent form agreeing to take part in the study and allowing their personal health information to be shared. - People who have been confirmed through a tissue or cell sample test to have adenocarcinoma of the pancreas (a specific type of panc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04005690 · OHSU Knight Cancer Institute Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to understand and willing to sign a consent form - People with a confirmed diagnosis of pancreatic adenocarcinoma (a specific type of pancreatic cancer) that is classified as resectable, borderline resectable, locally advanced, or metasta...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04048278 · University of Illinois at Chicago Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 8 November 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic cancer (including adenocarcinoma or other types of malignant pancreatic tumors) confirmed through tissue or cell testing - People who have at least one tumor that can be measured using medical imaging - People whose cancer was initia...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04074135 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 January 2036
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Von Hippel-Lindau (VHL) disease, either through genetic testing that found a specific gene change, or through clinical diagnosis based on symptoms and medical history. - People who have at least one sign of VHL affecting the pancreas (a gl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04084496 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that has been confirmed by laboratory testing and has not spread to distant parts of the body - People who have had surgery to fully remove their pancreatic cancer - People who have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04099134 · University of Ulm Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by tissue or cell testing, or who are strongly suspected of having this condition before surgery aimed at curing it - People who have not yet received any treatme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04136132 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇫🇷 FR

**Who might be able to join this trial:** - People who are over 18 years of age - People being treated for pancreatic adenocarcinoma (a type of pancreatic cancer) - People whose medical team considers them suitable for at least one surgery and chemotherapy - People who are willing and able to give their informed consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04146298 · Changhai Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with advanced pancreatic cancer that has spread or come back, confirmed by a laboratory test, and who have already received standard chemotherapy (and surgery, if the cancer returned after an operation). - People whose tumour has a specific gen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04150042 · General Oncology, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People diagnosed with stage IV pancreatic cancer or stage IV breast cancer (including those whose cancer responded completely to prior chemotherapy). - People whose doctor estimates they have at least 6 months life expectancy. - People whose overall hea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04157127 · Diakonos Oncology Corporation Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older, of any gender - People who have been diagnosed with a specific type of pancreatic cancer (adenocarcinoma or adenosquamous carcinoma) that doctors consider possibly removable by surgery, either upfront or after initial chemotherapy and/or r...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04239573 · ECOG-ACRIN Cancer Research Group Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇦 CA Puerto Rico🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - People who are aged between 50 and 75 years old. - People who have had a CT scan, MRI, or endoscopic ultrasound (a camera procedure to look inside the body) within the past 6 months that found one or more fluid-filled sacs (cysts) on the pancreas, each measuring at least 1 cm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04275557 · H. Lee Moffitt Cancer Center and Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been seen at a GI clinic, surgery department, or endoscopy unit and doctors suspect or have confirmed that you have a problem with your pancreas (such as a cyst, growth, cancer, or inflammation), based on your symptoms, scans, or blood tests. - You have not yet had a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04276857 · University of Saskatchewan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇦 CA

Who might be able to join this trial: - Adults who have been diagnosed with locally advanced pancreatic cancer (confirmed by a biopsy) and whose treating oncologist has determined they are suitable for combination chemotherapy. Who may not be able to join: - People who are pregnant. - People whose pancreatic cancer ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04291651 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - Adults aged 30 years or older - People who have been diagnosed with at least one pancreatic cyst through imaging (such as a scan) or a camera procedure, regardless of whether they are currently being treated for it - People with no history of pancreatic cancer - People who can sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04361708 · University of Chicago Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed (confirmed by a lab test) with a specific type of cancer in or near the digestive system, such as pancreatic cancer, stomach/esophagus cancer, bile duct cancer, gallbladder cancer, or a related type, that has spread locally or to other parts of the bo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04370574 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 January 2021
🇫🇷 FR

Who might be able to join this trial: - People who have a mass in the pancreas and are suspected of having a type of pancreatic cancer called pancreatic ductal adenocarcinoma, and who need a procedure where a doctor uses an ultrasound probe and a needle (passed through a small camera into the digestive tract) to take a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04406831 · Nuvance Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer) confirmed by a biopsy - People whose cancer was not able to be removed by surgery at the time of diagnosis, either because it has spread to nearby areas or to other parts of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04485286 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** *For people with lung cancer:* - People diagnosed with locally advanced non-small cell lung cancer (stage I–III) who are not able to have surgery, or those with stage IIIa who are planned for a combination of chemotherapy, radiation, and then surgery - People aged 18 years or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04570943 · Institut du Cancer de Montpellier - Val d'Aurelle Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 18 and 75 years old at the time of signing the consent form. - People whose pancreatic cancer has been confirmed through a tissue or cell sample (biopsy or similar test). - People who are largely able to carry out daily activities with little or no limita...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04575363 · CHU de Reims Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - People being treated at Reims University Hospital for a pancreatic tumour that can be surgically removed, or that may become removable after treatment, with or without pre-surgery chemotherapy - People aged 18 or older - People who have read and signed the trial's consent for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04588025 · Ohio State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: **Healthy Volunteers (a small group of 5 people):** - You are 19 years of age or older - You do not have any known major health conditions, including cancer, heart disease, diabetes, high blood pressure, high cholesterol, stroke, breathing problems, or arthritis - People of all ra...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04605913 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic adenocarcinoma or adeno-squamous carcinoma (specific types of pancreatic cancer) that has spread to the liver, confirmed through tissue or cell testing. - People whose cancer has spread to other parts of the body as well, as lon...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04616131 · Northwestern University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) confirmed by a tissue or cell sample test - People whose scans show no signs that the cancer has spread to other parts of the body - People aged 18 or older - People who are currently re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04622423 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇮🇹 IT

**Who might be able to join this trial:** **Colorectal cancer (CRC) group:** - People who have been diagnosed with colorectal cancer that has spread to the liver (confirmed by tissue or cell testing), classified as stage IV - People for whom surgery and/or chemotherapy has been recommended as a treatment option - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04665947 · University of California, Davis Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People with a confirmed diagnosis of pancreatic adenocarcinoma (a specific type of pancreatic cancer) that has spread or cannot be surgically removed, and where at least one measurable tumour or affected lymph node is visible on scan...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04678648 · RasCal Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with an advanced or spreading cancer that has either stopped responding to existing treatments, has continued to grow despite standard treatment, or where existing treatments have caused intolerable side effects. - People whose cancer has tumors...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04683315 · Medical College of Wisconsin Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are suspected of having pancreatic cancer and are scheduled for a procedure (endoscopy) to take a tissue sample for diagnosis. - You are willing to have a tissue sample taken during an endoscopic procedure for research purposes, or you can provide a previously collected...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04858009 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 80 years old - People whose general health and ability to carry out daily activities meets a certain standard, as measured by a medical scoring tool called the ECOG scale (score of 2 or below, meaning the person is able to be up and about for at least half...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04858334 · National Cancer Institute (NCI) Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 31 October 2027
🇮🇱 IL Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of giving consent - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (ECOG score of 0–2) - People who have been diagnosed with p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04881487 · UMC Utrecht Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who are already participating in the PACAP cohort study and have previously given written consent to be included in future randomised studies - People whose pancreatic cancer has come back only in the area where it was originally removed (called a local recurrence), wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04894643 · EBG MedAustron GmbH Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇦🇹 AT

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer confirmed through a tissue or cell sample test - People whose cancer has been classified as "borderline resectable" according to a specific international medical definition from 2017 (confirm with trial site) - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04969731 · GC Cell Corporation Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - You are between 20 and 80 years old - You have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by a tissue or cell sample - You have had surgery to remove the cancer (either fully or at the edges) at least 2 weeks ago but...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04990609 · The University of Texas Health Science Center, Houston Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) and had it confirmed through a biopsy (tissue sample test) - People who have a permanent home address - People who agree to take part in the study - People whose CT scan results are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05006131 · Beth Israel Deaconess Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2032
🇺🇸 US

**Who might be able to join this trial:** - People with a strong family history of pancreatic cancer — for example, having at least two close blood relatives (such as a parent or sibling) on the same side of the family who had pancreatic cancer, where at least one of those relatives is a parent, sibling, or child of t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05013216 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are considered high risk for developing pancreatic cancer (falling into one of three groups below) and are already taking part in a pancreatic monitoring programme, AND who have an abnormality found on a pancreas scan (such as a pancreatic cyst). - **High Risk Gr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05035147 · Tianjin Medical University Cancer Institute and Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People diagnosed with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery (excluding a specific type called islet cell carcinoma), confirmed by a tissue or cell sample - People who have not had standard can...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05037461 · J.M. de Laat Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇳🇱 NL

**Who might be able to join this trial:** - People who have a pancreatic neuroendocrine tumour (a type of slow-growing pancreatic tumour) measuring between 2 cm and 3 cm in size. - People who have a tumour between 1.0 cm and 2.0 cm that has been growing at a moderate rate (2–4 mm per year) based on a series of follow-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05040360 · SWOG Cancer Research Network Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 31 March 2027
🇲🇽 MX🇺🇸 US Uruguay

**Who might be able to join this trial:** - People who have been diagnosed with a well-differentiated pancreatic neuroendocrine tumour (a specific, slower-growing type of pancreatic tumour) that was surgically removed between 14 and 120 days before joining the trial - People who had a scan within the past 90 days show...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05052671 · University of Oklahoma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with exocrine pancreatic cancer, where either a tissue sample or imaging scan suggests it is adenocarcinoma (a specific type of pancreatic cancer) - People whose cancer is classified as resectable or borderline resectable (meaning surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05053555 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** **Group A (current patients):** - Adults aged 18 or older who have lesions (abnormal growths) in the liver - People with up to five liver tumors that cannot be surgically removed, where at least one of the following applies: the tumor is at least 3 cm in size; the tumor is loc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05058846 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2032
🇺🇸 US

**Who might be able to join this trial:** **Group I (no strong family history of pancreatic cancer):** - People who have a documented harmful or likely harmful genetic mutation in one of these genes: BRCA1, BRCA2, ATM, or PALB2 - People who do not have a close family history of pancreatic cancer — meaning no first-deg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05065801 · Institut du Cancer de Montpellier - Val d'Aurelle Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 to 75 at the time of signing the consent form - People with pancreatic cancer that has spread to other parts of the body (metastatic), confirmed by tissue or cell testing - People who have at least one measurable area of cancer spread, detectable by a chest, a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05076760 · Memgen, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study information and agree to take part voluntarily. - People who are willing and able to attend all required study visits and follow the study procedures. - Adults aged 18 or older. - People whose cancer has not significantly affected...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05083247 · Erasme University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇧🇪 BE

**Who might be able to join this trial:** - People who have been confirmed by a local pathologist to have a type of pancreatic cancer called adenocarcinoma, located in any part of the pancreas - People whose cancer is classified as "borderline resectable" (meaning surgery is possible but complex), confirmed by a team...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05086250 · Cedars-Sinai Medical Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 15 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand and willing to sign a written consent form - People who have been diagnosed with pancreatic cancer - People who are currently receiving, or who have received within the last 12 weeks, cancer treatment such as surgery, radiation, chemotherapy...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05088798 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a condition called hyperinsulinemic hypoglycemia (where the body produces too much insulin, causing dangerously low blood sugar levels), confirmed through blood tests or specific medical tests. - People for whom standard medications used to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05098197 · Shanghai Juncell Therapeutics Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 25 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years of age - People who have been diagnosed with primary, relapsed, or spread (metastatic) cancer of the liver, bile ducts, or pancreas, confirmed by a tissue sample - People whose doctors estimate they have a life expectancy of more than 3 months...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05102110 · Origin Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2027
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 years or older - People who are able to give their voluntary agreement to participate in writing Who may not be able to join: - People whose symptoms would make an internal examination of the lower bowel unsafe or unsuitable — for example, those with a painful tea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05116072 · University Hospital, Lille Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 February 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a specific type of cancer in the head of the pancreas (pancreatic adenocarcinoma, duodenal adenocarcinoma, ampullary adenocarcinoma, or a cyst-related cancer called IPMN with adenocarcinoma), confirmed by a spec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05128890 · Methodist Health System Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 April 2027
🇺🇸 US

Who might be able to join this trial: - People who had surgery to remove part or all of their pancreas or liver at Methodist Dallas Medical Center (MDMC) between January 2006 and December 2020 - People who were 18 years old or older at the time of their surgery Who may not be able to join: - People who did not have su...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05132244 · British Columbia Cancer Agency Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample. - You are planned to start a first-line chemotherapy treatment called FOLFIRINOX (meaning you have not yet had chemotherapy for your cur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05141513 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years old - People who have pancreatic cancer that has been classified as resectable, borderline resectable, or locally advanced, confirmed through CT scan, ultrasound, or other imaging - People who are in reasonably good general health, as measured by...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05155878 · Umeå University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2035
🇸🇪 SE

Who might be able to join this trial: - People who have been recommended surgery for a tumor or cyst in the pancreas or the area around it (called the periampullary region) - People whose relevant medical information is available in electronic health records - People who have given their informed consent to participate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05187312 · Region Stockholm Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 January 2032
🇸🇪 SE

Who might be able to join this trial: - People who have a medical reason that requires them to have an endoscopic procedure (a procedure where a small camera is used to look inside the body) Who may not be able to join: - People who have not given their formal written agreement to take part in the trial - People under...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05191940 · EBG MedAustron GmbH Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇦🇹 AT

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer, confirmed through a tissue or cell sample — or, in some cases, through scan findings combined with a raised CA 19-9 blood marker (confirm with trial site) - People whose cancer cannot be fully removed by surgery, either...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05193162 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇨🇳 CN

Who might be able to join this trial: - People aged 5 to 85 years old - People who, after review by a medical team, are able to have standard surgery, and whose surgical tissue sample confirms pancreatic cancer or another pancreatic condition - People who have not taken antibiotics or consumed yogurt containing probiot...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05195281 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 September 2027
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People who are willing to sign a consent form agreeing to take part in the trial - People who have had a CT scan, MRI, or endoscopic ultrasound (a camera procedure to look inside the body) showing that a pancreatic lesion is locally advan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05196334 · Herlev Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
🇩🇰 DK

Who might be able to join this trial: - People who have given their signed consent to participate - People who have been confirmed through tissue testing to have pancreatic ductal adenocarcinoma (a type of pancreatic cancer) and are planned to start standard first-line treatment, OR people suspected of having locally a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05218889 · Chinese PLA General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been fully informed about the study and have voluntarily agreed to take part by signing a consent form - People whose pancreatic cancer has been confirmed by laboratory tissue or cell testing, and whose cancer cannot be surgically removed, has spread to nearb...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05243082 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 January 2025
🇳🇴 NO

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who have been diagnosed with a pancreatic neuroendocrine tumor (a specific type of pancreatic tumor) confirmed by a tissue sample taken during an internal ultrasound procedure, and whose tumor is classified as a lower-grade t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05245877 · Helsinki University Central Hospital Phase 4 · 3 countries Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇨🇦 CA🇫🇮 FI🇳🇴 NO

**Who might be able to join this trial:** - People who are scheduled to have a surgical procedure called a pancreaticoduodenectomy (removal of part of the pancreas and surrounding structures) or total pancreatectomy (removal of the entire pancreas), for any medical reason - People who are scheduled to have a distal pan...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05257434 · Kochi University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2025
🇯🇵 JP

**Who might be able to join this trial:** - People who have had surgery as part of their treatment. **Who may not be able to join:** - People who lost more than 10% of their body weight in the 6 months before their surgery. - People who have cancer that has spread to distant parts of the body (known as distant metasta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05257993 · Onconic Therapeutics Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2030
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) that cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, confirmed by laboratory testing of tissue or cell samples - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05268692 · Kochi University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2025
🇯🇵 JP

**Who might be able to join this trial:** - You are scheduled to have planned (non-emergency) surgery to remove part or all of the pancreas due to pancreatic cancer **Who may not be able to join:** - You have previously had surgery for cancer - You have lost more than 10% of your body weight in the 6 months before sur...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05288205 · Allist Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

Who might be able to join this trial: - People who have signed a written consent form before any study procedures begin (or whose legal representative has signed on their behalf) - People who have a solid tumour that has been confirmed by lab testing, is locally advanced or has spread to other parts of the body, and ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05296421 · Rutgers, The State University of New Jersey Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma), confirmed by a biopsy, and your doctors believe surgery to remove the cancer may be possible - You are willing to have small tissue samples (biopsies) ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05298722 · University Hospital, Ghent Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇧🇪 BE🇳🇱 NL

Who might be able to join this trial: - People aged 18 years or older - People diagnosed with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), as defined by standard oncology guidelines (confirm with trial site) - People whose cancer diagnosis has been c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05334836 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
Hong Kong

**Who might be able to join this trial:** - People aged 18 or older - People who have at least one fluid-filled sac (cyst) in the pancreas, measuring 5mm or larger, that has been identified by a scan (CT, MRI, or endoscopic ultrasound) as a possible IPMN or MCN (specific types of pancreatic cysts) — or people who are g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05346536 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 September 2025
🇫🇷 FR

Who might be able to join this trial: - You are at least 18 years old - You have been diagnosed with pancreatic cancer that has spread to other parts of the body, and you have not yet received any treatment for it (meaning you are eligible for your first round of treatment) - You are able to give verbal agreement to ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05356039 · Umeå University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇸🇪 SE

**Who might be able to join this trial:** - People who have a confirmed or suspected pancreatic tumour that has grown into surrounding tissue - People whose tumour has been classified as either "borderline resectable" (potentially removable by surgery) or "locally advanced" (has spread nearby but not to distant parts o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05356117 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with pancreatic cancer that has not spread to other parts of the body, who are about to start chemotherapy before surgery - People aged 18 or older - People who speak English or Spanish - People who are willing and able to sign a consent form agreeing to take...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05376592 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2031
🇺🇸 US

Who might be able to join this trial: - People who are willing to sign a consent form allowing their personal health information to be used by the Levine Cancer Institute and Atrium Health - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with pancreatic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05379985 · Revolution Medicines, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2027
🇺🇸 US

**Who might be able to join this trial:** - Your cancer must be an advanced solid tumor that has been confirmed by a lab test (biopsy), with a specific genetic change (mutation) in a gene called KRAS G12 or RAS, found through DNA testing — or, for one part of the trial, a pancreatic cancer without a RAS mutation - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05380414 · Centre Leon Berard Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

Who might be able to join this trial: - People who are over 18 years old, of any gender - People who have pancreatic cancer (a specific type called PDAC) that has spread or is at an advanced stage - People who have received no more than one previous chemotherapy treatment for their advanced or spread cancer (radiation...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05391126 · Reema A. Patel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic cancer (stage I–IV) or colorectal cancer (stage III–IV) through a laboratory test on tissue samples, and who are planning to receive treatment. - People who have previously had surgery, radiation therapy, or chemotherapy that did not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05394259 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 2 February 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older (children are not included in this trial because safety information for that age group is not yet available). - People whose general health and ability to carry out daily activities meets a minimum functional level, as assessed by their doctor (confirm wit...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05403554 · Light Chain Bioscience - Novimmune SA Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 30 May 2026
🇫🇷 FR🇮🇹 IT

**Who might be able to join this trial:** *For the dose escalation and combination treatment parts of the trial:* - People who are 18 years of age or older - People who have been diagnosed with a specific type of ovarian cancer (high-grade serous or endometrioid epithelial ovarian cancer), triple-negative breast canc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05424159 · Shanghai Proton and Heavy Ion Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand and sign a written consent form agreeing to take part in the study - People who have been diagnosed with a specific type of pancreatic cancer called ductal adenocarcinoma, confirmed by a tissue or cell sample test - People whose cancer has not sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05428358 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇰 DK

**Who might be able to join this trial:** - People who have pancreatic cancer where the tumour has been assessed by a specialist medical team as removable by surgery, or close to being removable by surgery - People whose CT scan shows no cancer spread to the liver - People who are at least 18 years old and are able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05431270 · Phanes Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People who have at least one tumour that can be measured using standard imaging guidelines - For Part A: People who have been confirmed (by lab testing of tissue or cells) to have an advanced or spreading solid tumour that cannot be surgically removed, and who have already tried...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05433935 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2032
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with IPMN (a type of pancreatic cyst condition) - People who do not have any other type of cancer or malignant tumour - People who are willing to sign a consent form agreeing to take part in the trial Who may not be able to join: - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05438667 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are over 18 years old. - People who have been diagnosed with an advanced solid tumour (confirmed by lab testing of tissue or cells) that has not responded to standard treatments, where standard treatments are not tolerated, or where no standard treatment exists —...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05451043 · AHS Cancer Control Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 years or older who weigh more than 30 kg (about 66 pounds) - People with an expected survival of at least 12 weeks - People who have been diagnosed with advanced pancreatic cancer, liver cancer (hepatocellular carcinoma), or bile duct/gallbladder cancer (bilia...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05462496 · Icahn School of Medicine at Mount Sinai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - A diagnosis of pancreatic adenocarcinoma (a specific type of pancreatic cancer) that has been confirmed by a tissue sample — other types of pancreatic cancer are not eligible - Cancer that has been staged as T1–T3, N0–N2, M0, meaning it has not spread to distant parts of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05463796 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People who carry known gene changes (mutations) that raise their risk of developing cancer - People with a personal or family history that suggests a higher-than-average cancer risk, even if genetic testing came back negative or has not been done - People who have been clini...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05475366 · Institut Curie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 December 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are willing and able to sign a consent form before any trial-related procedures begin. - You are willing and able to follow the trial schedule, including all visits, treatments, and check-ups. - Your pancreatic cancer has been confirmed by a lab test (biopsy or cell samp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05501379 · University Medicine Greifswald Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇩🇪 DE

Who might be able to join this trial: - People with a confirmed diagnosis of lymphoma, colorectal cancer, or pancreatic cancer - People whose treatment plan includes surgery, chemotherapy, or radiation therapy - People who have agreed to take part by signing an informed consent form Who may not be able to join: - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05518903 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults over 18 years old who have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer), either confirmed by a tissue sample (biopsy) or by imaging scans such as CT, MRI, or PET, and have not yet received any treatment for it - People whose cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05524090 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇳🇱 NL

Who might be able to join this trial: - People aged 18 years or older. - People who have been diagnosed with locally advanced pancreatic cancer (cancer that has grown into nearby blood vessels but has not spread to other parts of the body), confirmed by a pathology test. - People whose cancer has not grown or spread (a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05526443 · Medical University of Graz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇦🇹 AT

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People whose ability to carry out daily activities falls within a certain range, meaning they are fully active or have some limitations but are still able to care for themselves (confirm with trial site) - People who have been diagnosed wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05529940 · Seoul National University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2024
🇰🇷 KR

**Who might be able to join this trial:** - People aged 19 to 80 years old - People with a good general health and activity level, as measured by a standard medical scoring tool called the ECOG scale (score of 0 or 1), meaning they are fully active or have only minor limitations in physical activity - People whose pan...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05556603 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2029
🇨🇳 CN

Who might be able to join this trial: **Cancer Arm (people with a recent cancer diagnosis):** - People aged 40 to 75 years old. - People who are able to sign a written consent form. - People who have not yet received any cancer treatment, and either have a confirmed cancer diagnosis made within the past 42 days, or ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05604716 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇨🇳 CN

Who might be able to join this trial: - People who have had surgery and received a confirmed medical diagnosis of a solitary pulmonary nodule (a small spot found on the lung) based on the surgical findings - People who have given their agreement to take part in the trial - People whose questionnaire responses are compl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05606523 · Genton Graf Laurence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇨🇭 CH

**Who might be able to join this trial:** *People with pancreatic cancer (12 spots):* - Adults aged 18 or older who have recently been diagnosed with pancreatic cancer (whether it has spread or not) and who have been on tube feeding or IV nutrition for 14 days or less *Within that group, people with cachexia (signifi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05624918 · Ashish Manne Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are male, or female and neither pregnant nor breastfeeding at the time of signing consent forms. - People who are well enough to carry out most daily activities, as measured by a standard health performance scale (a score of 70% or higher on the K...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05625529 · Biological Dynamics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who meet the criteria for one of the specific groups being studied in this trial (confirm with trial site) - People who are able to understand and agree to participate in the study - People who are able to provide a blood sample W...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05653453 · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 25 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - Your doctor expects you to live for at least 3 more months - You have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample - Your cancer is locally advance...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05679674 · Baptist Health South Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced pancreatic cancer (a type of cancer that has not spread to distant parts of the body), confirmed by laboratory testing of tissue or cell samples, as defined by National Comprehensive Cancer Network guidelines. - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05687123 · National Cancer Institute (NCI) Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 14 December 2026
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed (through a tissue or cell sample) with pancreatic neuroendocrine tumors (PNETs) that have spread or cannot be surgically removed, of any grade (1, 2, or 3) - People whose tumors show up on a special type of scan (SSR PET/CT) that confirms the tumor...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05687188 · H. Lee Moffitt Cancer Center and Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults who are 18 years of age or older at the time of signing the consent form - People who identify themselves as African American or Non-Hispanic White - People who are visiting a GI (digestive health) clinic, surgery department, or endoscopy unit at a participating Florid...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05714111 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2027
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years of age or older - You either have been diagnosed with pancreatic cancer at any stage, or your doctor suspects you may have pancreatic cancer and is planning to investigate it further - You must be willing and able to agree to take part by signing a consent fo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05720338 · Case Comprehensive Cancer Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are scheduled to have a planned surgery to remove part of your pancreas (the left side), with or without also having your spleen removed - You are 18 years old or older - You are able to understand the study information and are willing to sign a consent form agreeing to t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05723107 · NYU Langone Health Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed through a tissue biopsy. - People who have had a CT scan or MRI showing the pancreatic cancer measures at least 1 cm at its widest point. - People whose general h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05724992 · Associazione Italiana per lo Studio del Pancreas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 December 2027
🇮🇹 IT

Who might be able to join this trial: - You must already be registered on a specific Italian registry for people with a family history of pancreatic cancer (called the IRFARPC registry). - You must have a known family connection to pancreatic cancer, as defined by specific guidelines used by that registry. - You must b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05727020 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇬🇧 GB

**Who might be able to join this trial:** - People of any gender aged 18 or older - For the VAPOR 1 part of the trial: people who have been diagnosed with pancreatic cancer (confirmed by tissue testing), people who have recently developed diabetes or have chronic pancreatitis, or people with general digestive symptoms...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05737953 · Zhaoshen Li Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have had imaging tests (such as ultrasound, CT scan, or MRI) that identified a cyst or suspected cystic tumour on the pancreas - People who have agreed to undergo surgical removal of the pancreatic cystic tumour - People (or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05743049 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected to have, a type of pancreatic cancer called pancreatic adenocarcinoma. - People who are currently a patient at the University of Pennsylvania. - People who are able to understand and agree to take part in the study (give i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05746182 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with a pancreatic neuroendocrine neoplasm (a type of tumour in the pancreas), confirmed by a tissue sample taken from any location in the body, such as the original tumour site or a spread (metastatic) site. - Both newly diagnos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05752812 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇦🇹 AT

**Who might be able to join this trial:** - People who are 18 years of age or older - People who are healthy enough to undergo a planned surgical removal of part of the pancreas, or to receive palliative (comfort-focused) treatment - People who have been diagnosed with a specific type of pancreatic cancer called pancre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05764720 · Varian, a Siemens Healthineers Company Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that is either borderline removable by surgery, too advanced for surgery, or where surgery is not safe for medical reasons, confirmed by a tissue or cell sample. - People who are general...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05776524 · THERABIONIC INC. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with metastatic pancreatic adenocarcinoma (a specific type of pancreatic cancer that has spread to other parts of the body) that has been confirmed by biopsy and has not yet been treated. - People who have at least one measurable tumor th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05779917 · Second Affiliated Hospital of Guangzhou Medical University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 10 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have advanced cancer where the tumour cells carry a protein called Mesothelin. - People who are expected to live for more than 12 weeks. - People whose heart, lungs, liver, kidneys, and blood are all functioning well enough to meet the trial's requirements. - Peop...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05784311 · Leiden University Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2025
🇳🇱 NL

Who might be able to join this trial: - People who are scheduled to have a planned (non-emergency) surgical procedure called a pancreatoduodenectomy (a major operation involving the pancreas and nearby organs), and who have a higher chance of having bacteria in their bile — either because they had a tube placed before...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05788744 · Copenhagen University Hospital at Herlev Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇩🇰 DK

"Who might be able to join this trial: **Sub-study 1:** - You are suspected of having pancreatic cancer (at an early to intermediate stage, not yet spread widely) and are scheduled for surgery to remove part of the pancreas, with or without receiving chemotherapy beforehand. **Sub-study 2:** - You have been diagnosed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05802394 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer through a tissue sample (biopsy), where the tumour is either on the borderline of being removable by surgery, or has grown into nearby areas but has not spread to distant parts of the body. - People for whom doctors have p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05821556 · National Cancer Institute, Naples Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇮🇹 IT🇪🇸 ES

**Who might be able to join this trial:** - People who have given written consent to take part in the study and its related tests. - People who have been diagnosed with pancreatic cancer (PDAC) that has spread to other parts of the body, confirmed by a tissue or cell sample. - People who have not yet received any trea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05827796 · InxMed (Shanghai) Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who fully understand the study and are willing to sign a consent form agreeing to take part. - Adults aged 18 or older at the time of signing the consent form. - People who have been diagnosed with a specific type of pancreatic cancer (pancreatic ductal adenocarcinoma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05837767 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 July 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed (confirmed by biopsy) with advanced or spread (metastatic) solid tumours of specific cancer types: breast cancer (all subtypes), non-small cell lung cancer, gastrointestinal cancers including pancreatic cancer, bladder cancer, kidney cancer, melanom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05841420 · Morten Ladekarl Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇩🇰 DK

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample - People whose pancreatic cancer cannot be surgically removed, either because it has spread to nearby areas or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05843877 · Technische Universität Dresden Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇩🇪 DE

**Who might be able to join this trial:** - People who are suspected of having or have been diagnosed with a tumour near the area where the pancreas meets the small intestine (called a periampullary tumour), and for whom a specific type of pancreatic surgery (called a Whipple procedure or pylorus-preserving pancreatic...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05845801 · Azienda Ospedaliera Universitaria Integrata Verona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2052
🇮🇹 IT

**Who might be able to join this trial:** - You were diagnosed with pancreatic cancer at age 55 or younger. - You are at least 18 years old. - You are willing and able to sign a written consent form to take part in the study. **Who may not be able to join:** - You have a type of pancreatic or nearby tumor that is not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05847855 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People whose tissue biopsy results confirm one of three specific types of pancreatic tumour: a non-functional pancreatic neuroendocrine tumour, pancreatic ductal adenocarcinoma, or solid pseudopapillary tumour - People who have not rec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05851534 · Maastricht University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 September 2027
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 or older who are planned to have surgery to remove part or all of the pancreas, with the goal of curing their condition, at one of the hospitals in the Dutch Pancreatic Cancer Group that performs this type of surgery - People whose surgery may or may not include tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05859750 · Akeso Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand and willingly sign a consent form before any study procedures begin - People aged 18 to 75 years old at the time of signing the consent form - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05869474 · Changhai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old - People who have been confirmed, through clinical assessment, imaging, and tissue testing, to have Stage IV pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) that has spread to distant parts of the body, with tumours that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05871164 · GCS Ramsay Santé pour l'Enseignement et la Recherche Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2030
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who are being treated for a pancreatic tumour using a procedure called radiofrequency ablation, which uses heat delivered through a fine needle guided by ultrasound - People whose case has been reviewed and approved for this procedure by a t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05873699 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have one or more cysts on their pancreas - People who are scheduled to have surgery or a tissue sample taken from a pancreatic cyst - People who are able to understand the study and are willing to sign a consent form - Both English-speaking and non-Eng...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05884255 · Jiangsu HengRui Medicine Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate - People aged 18 to 75 years old, of any gender - People whose general health and ability to carry out daily activities is rated at a good level (ECOG score of 0 or 1 — confirm with trial site if unsure w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05911217 · CARsgen Therapeutics Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily, have been fully informed about the study, and have signed a consent form - People aged 18 to 79 years - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05914987 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older. - People who have been diagnosed with pancreatic cancer that has been confirmed through laboratory testing of tissue samples. - People who are able to understand and willing to sign a written consent form. Who may not be able to join: - People under the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05916261 · Ruijin Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and are willing and able to follow the study's procedures, as judged by the research team - People who are 18 years of age or older at the time of signing the consent form, of any gender - People who have been diagnosed with lo...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05927142 · Joachim Aerts, MD PhD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with metastatic pancreatic cancer, confirmed by a tissue or cell sample analysis. - People whose cancer has been stable (not grown or spread) after receiving at least 8 cycles of a chemotherapy regimen called FOLFIRINOX, based on standard measu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05929885 · National Cancer Centre, Singapore Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇸🇬 SG

**Who might be able to join this trial:** - People aged 21 or older - People who have been diagnosed with pancreatic cancer confirmed by a tissue or cell sample - People whose cancer is at an advanced stage and cannot be fully removed by surgery (either locally advanced or spread to other parts of the body) - People w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05939063 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with pancreatic cancer on the left side of the pancreas that doctors have determined can be removed with surgery. - People whose tumor measures 4 cm (about 1.5 inches) or less in size on imaging scans. - People whose tumor is located at l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05961982 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with a pancreatic cyst (known as a pancreatic cystic neoplasm) confirmed through specific specialist procedures, including fluid testing and/or imaging techniques performed during an endoscopic ultrasound - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05968326 · Genentech, Inc. Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 1 January 2031
🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇳🇱 NL🇰🇷 KR🇪🇸 ES🇸🇪 SE +2 more

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by laboratory testing of tissue - People whose cancer has been staged at certain levels — not too advanced — based on the size of the tumor, whether it has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05969171 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and have signed a consent form - People with pancreatic cancer that cannot be removed by surgery, or that has spread locally or to other parts of the body, confirmed by a tissue or cell sample test - People aged between 18 and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05975593 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2032
🇺🇸 US

Who might be able to join this trial: - People who are planning to receive radiotherapy (radiation treatment) for either cervical cancer or pancreatic cancer - People who are reasonably able to carry out daily activities with little to no limitation from their illness (this is measured on a standard scale used by docto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05984810 · Leiden University Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇳🇱 NL

**Who might be able to join this trial:** *For patients with pancreatic cancer (Part A):* - You are 18 years of age or older - You have been diagnosed with pancreatic cancer that has been treated with pre-surgery therapy (neoadjuvant treatment) and you are scheduled to have surgery to remove the tumour - You are able...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05985655 · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuti... Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇧🇪 BE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who are reasonably well and able to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, scored 0 or 1). - People with a life expectancy of more than 3 months. - People who have been confirmed (through tissue or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05988814 · Centre Georges Francois Leclerc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 July 2029
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older at the time of joining the study - People whose general health and ability to carry out daily activities is rated as 0 or 1 on a standard oncology scale (meaning fully active or able to do light work) - People diagnosed with a specific type of pancreatic c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06008288 · Allist Pharmaceuticals, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have a specific genetic mutation called KRAS G12C, confirmed through an approved diagnostic test. - People who have been diagnosed with a locally advanced (cannot be surgically removed) or metastatic solid tumour (cancer that has spread), in any organ except the l...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06017284 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 November 2025
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand the study and are willing to sign a written consent form - People aged 18 to 80 years old - People whose general physical functioning is rated at a level that allows them to carry out daily activities with little to moderate limitation (confirm w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06018896 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form. - People aged between 18 and 80 years old. - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard oncology...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06043921 · Invitae Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇯🇵 JP

**Who might be able to join this trial:** *For people with pancreatic cancer that cannot be removed by surgery:* - You are at least 20 years old at the time of signing the consent form - Your pancreatic cancer has been confirmed by a lab test to be a specific type called adenocarcinoma, diagnosed within the last 60 da...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06046794 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with metastatic pancreatic cancer (a type of cancer that has spread beyond the pancreas), confirmed by a tissue test. - People who are not able to receive a chemotherapy combination called FOLFIRINOX and are about to start first-line treatment with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06050317 · Shandong Cancer Hospital and Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 18 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People whose general physical condition is rated as fully active or restricted only in physically strenuous activity (this is measured using a standard health performance scale called ECOG, scores 0–1) - People who have been confirmed by tissue testing to have locally advanc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06055010 · UMC Utrecht Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇳🇱 NL

Who might be able to join this trial: - People who are 18 years of age or older - People who have had tests or treatment for a suspected or confirmed pancreatic condition (either non-cancerous or cancerous) and whose information is already recorded in a Dutch medical database called the PACAP audit, or healthy people w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06069297 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years of age or older - You have been recommended for surgery with the goal of curing pancreatic or periampullary cancer (a type of cancer near the pancreas) - You are willing and able to sign a consent form agreeing to take part Who may not be able to join: - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06073431 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 November 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with either advanced (stage IV) or inoperable non-small cell lung cancer, pancreatic adenocarcinoma (a type of pancreatic cancer), or colorectal cancer — a cachexia (muscle-wasting) diagnosis is not required to be considered. - People who are about...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06078787 · Azienda Ospedaliero-Universitaria di Modena Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory testing of tissue or cell samples. - People whose pancreatic cancer is advanced — meaning it cannot be surgically removed or has spread to other...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06079346 · Oncotelic Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with advanced, inoperable, or metastatic pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue sample from the pancreas or another affected area. - People whose cancer can be measured on scans, according to standard...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06084013 · OHSU Knight Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who are scheduled to have an open surgical procedure on the pancreas (either removing the head of the pancreas or the tail/body of the pancreas) for any medical reason - People who are 18 years of age or older - People who are able to understand what the trial involves and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06111274 · Abbisko Therapeutics Co, Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, both male and female, who are willing to give written consent to participate. - People who have been diagnosed with pancreatic cancer that cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, confirm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06121622 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇮🇹 IT

Who might be able to join this trial: - You are having surgery to remove a specific type of pancreatic tumor called a non-functioning pancreatic neuroendocrine tumor (a type of slow-growing tumor in the pancreas that does not produce excess hormones) - You are 18 years old or older - You have given your written agreeme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06122896 · Dana-Farber Cancer Institute Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 October 2040
🇺🇸 US

**Who might be able to join this trial:** - People who carry a harmful gene change in *STK11* and are aged 30 or older - People who carry a harmful gene change in *CDKN2A* and are aged 40 or older — or aged 10 years younger than the earliest pancreatic cancer diagnosis in their family, whichever age comes first - Peop...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06128343 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2035
🇫🇷 FR

**Who might be able to join this trial:** - People who have a mass (lump or growth) in the pancreas that has been examined using a procedure called endoscopic ultrasound (a camera with sound waves), which may have included taking a small tissue or fluid sample - People who have a mass in the pancreas that has been exam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06135896 · National Cancer Center, Korea Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇰🇷 KR

Who might be able to join this trial: - People aged 19 years or older who have been diagnosed with pancreatic or bile duct cancer that cannot be surgically removed, and whose doctor has planned for them to receive a specific combination chemotherapy treatment called nal-IRI/5-FU/LV Who may not be able to join: - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06139042 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** *Cancer Group:* - You are between 40 and 75 years old on the day you sign up for the study - You are able to read and sign a consent form agreeing to take part - You have been diagnosed with liver, bile duct, or pancreatic cancer, confirmed by a medical test - You have not had...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06141031 · Washington University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that is either "borderline resectable" (possibly removable by surgery) or "locally advanced" (spread nearby but not to distant parts of the body), and surgery is not expected to require re...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06144762 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2029
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older - You have been diagnosed with pancreatic cancer that has been confirmed through a tissue or cell sample (biopsy), and your doctors have planned for you to have surgery either straight away or after chemotherapy treatment first - Women who cou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06145074 · Zealand University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇩🇰 DK

**Who might be able to join this trial:** - You have suspected pancreatic cancer that doctors believe can be removed with surgery - You are being considered for surgery with the goal of curing the cancer - You are willing and able to sign a consent form agreeing to take part - You are at least 18 years old - If you ar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06148298 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with pancreatic cancer Who may not be able to join: - Children and anyone under the age of 18 are not eligible to register - People who are unable to give their own informed consent to participate are not eligible to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06149546 · Cancer Trials Ireland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇮🇪 IE

Who might be able to join this trial: - People who are able to give signed consent and are willing and able to follow the study requirements. - People who are 18 years of age or older. - People who have been newly diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a pat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06149689 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form - People aged 18 to 80 years old - People whose general physical ability and daily functioning falls within an acceptable range, as measured by a standard oncology scale (confirm with t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06151223 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2031
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are able to read, understand, and sign a consent form agreeing to take part in the trial - People who meet the trial's specific definition of being a "High-Risk Individual" (confirm with trial site for exact details) Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06151262 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People with a good general health and activity level (rated 0 or 1 on a standard medical scale called the ECOG scale, meaning largely able to carry out normal daily activities) - People whose doctors expect them to live for at least 1...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06158139 · UNC Lineberger Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give written consent to take part and to allow their personal health information to be shared as part of the study. - People who are 18 years of age or older at the time of giving consent. - People who have a relatively good level of physic...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06159478 · National Cancer Center, Japan Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇯🇵 JP

**Who might be able to join this trial:** **Criteria that apply to all participants:** - A BRAF gene fusion or rearrangement has been detected through an approved genetic test, including blood-based tests. - The cancer cannot be fully removed by surgery, or it has come back after previous treatment. - Any brain, spin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06160596 · Cure 51 Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇫🇷 FR

**Who might be able to join this trial:** *For "exceptional survivors" (people who lived much longer than expected with their cancer):* - People who were 18 years old or older when they were diagnosed - People diagnosed with one of three specific cancers in an advanced (spread) stage: pancreatic ductal adenocarcinoma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06164769 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a non-cancerous or low-risk tumour of the pancreas (such as pancreatic neuroendocrine tumours, solid pseudopapillary tumours, or cystadenomas) that has not spread to nearby blood vessels or other parts of the body - People whose tumour is locat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06166147 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇨🇳 CN

Who might be able to join this trial: **Cancer Arm (for people with pancreatic cancer):** - People between 40 and 75 years old - People who have been diagnosed with pancreatic cancer through clinical assessment and/or laboratory/tissue testing - People who have not received, and are not currently receiving, any cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06173310 · Ohio State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

Who might be able to join this trial: - People who are 19 years of age or older. - People who have been recently diagnosed with borderline resectable pancreatic cancer (a form of pancreatic cancer that may be on the border of being removable by surgery) and have not yet received any treatment for it. - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06182072 · ProDa BioTech, LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form. - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer) that has spread to other parts of the body (stage IV), confirmed by a tissue or cell sample. - For the firs...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06196788 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are able to understand and willing to sign a consent form agreeing to take part in the study. - You are between 18 and 80 years old. - You are able to carry out basic daily activities and care for yourself, with at most some limitations (confirm with trial site). - Your c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06198400 · Charles University, Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇿 CZ

Who might be able to join this trial: - People who are having open pancreaticoduodenectomy (a major surgery to remove part of the pancreas and nearby structures) at the participating hospital during the study period Who may not be able to join: - People who have a known allergy to indocyanine green (a dye used during...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06202066 · Roswell Park Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who are largely able to care for themselves day-to-day, with only occasional help from others - People who have a confirmed diagnosis of a neuroendocrine tumor originating in the gastrointestinal tract, pancreas, or chest with specific tumor...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06202131 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇮🇹 IT

Who might be able to join this trial: - Adults aged over 18 years old - People whose general health and ability to perform daily activities is rated at a reasonably functional level (a medical score called ECOG Performance Status below 2 — confirm with trial site) - People who have a confirmed tissue-based diagnosis of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06205849 · University of California, San Diego Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You are willing to sign a consent form and agree to follow all study requirements for the full duration of the trial - You have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by a tissue or cell sample - You are older th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06218914 · AstraZeneca Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People diagnosed with non-small cell lung cancer, colorectal cancer, pancreatic cancer, endometrial cancer, or another type of solid tumour - People whose tumour has a specific genetic change called a KRAS G12D mutation, and who also carry certain i...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06224387 · CytosinLab Therapeutics Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form - People with an advanced solid tumour (such as pancreatic cancer, non-small cell lung cancer, stomach cancer, or colorectal cancer, among others) that has been confirmed by laboratory testing of tissue or cell...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06228599 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with pancreatic cancer confirmed by a laboratory test (not the neuroendocrine type) - People whose pancreatic tumor has been surgically removed, and who have either received additional treatments such as chemotherapy o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06245330 · Ascentawits Pharmaceuticals, Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2027
🇨🇳 CN

**Phase I – Dose Escalation (for people with various solid tumours)** Who might be able to join this trial: - People aged 18 to 70 years (male or female) who are able to understand the study risks, are willing to follow the study procedures, and have signed a consent form - People with a solid tumour (confirmed by lab...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06249321 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and are willing to sign a written consent form - People aged 18 to 80 years old - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (confi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06250972 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 80 years old. - People who are able to understand the study and are willing to sign a consent form. - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (called...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06252545 · UNC Lineberger Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

Who might be able to join this trial: - You must be willing and able to give your consent to take part in the study - You must be 18 years old or older - You must be able to speak English - You must be able and willing to take part in a one-hour interview - You must have been diagnosed with pancreatic cancer at some po...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06271291 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇺🇸 US

**Who might be able to join this trial:** **Based on family history or genetics:** - People aged 50 or older who have two or more relatives on the same side of the family diagnosed with pancreatic cancer, where at least two of those relatives are closely related to each other and at least one is a close blood relative...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06277531 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇨🇳 CN

Who might be able to join this trial: - People who have a narrowing in their bile duct that doctors have not yet been able to identify the cause of - People for whom a procedure called ERCP (a type of internal examination of the bile ducts) has been recommended by their doctor Who may not be able to join: - People in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06278454 · Chengdu New Radiomedicine Technology Co. LTD. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old who are able to understand and sign a consent form - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample - People whose cancer has been assessed by a doctor...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06282809 · HistoSonics, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇪🇸 ES

Who might be able to join this trial: - People who are 18 years of age or older. - People who are willing to sign a consent form approved by an Ethics Committee before any trial-related tests or procedures, and who are willing to follow the trial steps and attend required follow-up visits. - People who have been diagno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06287749 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2028
🇫🇷 FR

Who might be able to join this trial: - People diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by a specialist medical team. - People aged 18 years or older. - People who are scheduled to have surgery with the goal of fully removing the cancer. Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06291324 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have pancreatic cancer or invasive breast cancer, and who are planning to start or have already started cancer treatment - People who report experiencing fatigue at any level - People aged 18 or older at the time of signing consent - People who are able to read and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06305728 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 March 2030
🇺🇸 US

**Who might be able to join this trial:** - Men and women who are over 18 years old - People who have a cyst on their pancreas that has been assessed as high risk and needs to be removed by surgery - People who are able to understand and agree to take part in the study by giving informed consent **Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06313970 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form - People aged 18 to 75 years old - People whose cancer has been confirmed by a tissue or cell sample to be pancreatic ductal adenocarcinoma or adenocarcinoma - People who have not yet received any system...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06320990 · University of Nebraska Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 19 years of age or older - You have been diagnosed with a specific type of non-cancerous pancreatic cyst called a mucinous cystic neoplasm (MCN) that can be measured on a scan - Your doctors are not planning surgery to remove the cyst, either because of the cyst's fea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06326736 · Jinling Hospital, China Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part in the study and sign a consent form agreeing to participate. - People who are 18 years of age or older at the time they sign the consent form. - People who have a pancreatic tumour that scans suggest can be fully removed by surgery and that ap...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06332274 · Gustave Roussy, Cancer Campus, Grand Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2029
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have finished surgery and all related treatments around the time of their operation, following standard international guidelines. - People who completed their main cancer treatments (such as surgery, chemotherapy before or after surgery)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06340620 · Orlando Health, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who are already scheduled to have an internal ultrasound procedure (called EUS) to examine the pancreas, bile duct, lymph nodes in the chest or abdomen, or abnormal growths in the food pipe, stomach, small intestine, or large bowel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06344156 · Sichuan University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old. - People with a good general health and activity level (rated as fully active or restricted only in physically demanding activity, confirmed with trial site). - People who have been diagnosed with a specific type of pancreatic cancer (pancreatic du...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06349278 · Laval University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 January 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who have a confirmed diagnosis of a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC). - People whose main pancreatic tumour can be surgically removed, as shown on a specialised type of CT scan. - People with no more than 3 cancer spots...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06353646 · Wu Wenming Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part in the study - People aged 18 to 75 years old - People who have been confirmed through tissue or cell testing to have pancreatic adenocarcinoma (a specific type of pancreatic cancer) - People who have had...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06359275 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed a consent form after being fully informed about the trial's purpose, expected effects, and risks - People who have been diagnosed with locally advanced pancreatic adenocarcinoma confirmed by tissue or cell testing, or people who have pancreatic cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06361888 · Hutchmed Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and able to follow the study requirements after signing a consent form - You are between 18 and 75 years old (inclusive) - You have been diagnosed with pancreatic cancer confirmed by a tissue or cell sample test - Your pancreatic cance...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06368063 · Xi'an Jiaotong University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (any gender) - You have been diagnosed with pancreatic cancer confirmed by a tissue sample (biopsy or surgery), and you had surgery to remove the cancer within the last 12 weeks before joining the trial - You did not receive any treatment b...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06375473 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by a biopsy or medical imaging scan - You are 18 years of age or older (any gender) - You are currently receiving a treatment that includes a medication called irinotec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06384560 · Amsterdam UMC, location VUmc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma), confirmed by a tissue or cell sample - You are 18 years of age or older - Your cancer is considered removable by surgery, or "borderline" removable (meaning it may be possible with treatm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06385925 · Tyligand Pharmaceuticals (Suzhou) Limited Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 30 October 2026
🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - People who fully understand what the study involves and have signed the consent form voluntarily. - People who are at least 18 years old at the time of signing the consent form (and no older than 75 for certain groups in this trial). - People who have a life expectancy of at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06387342 · Can-Fite BioPharma Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 July 2026
🇮🇱 IL

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender. - People who have been diagnosed with pancreatic adenocarcinoma (a type of pancreatic cancer), either confirmed through a tissue or cell sample, or diagnosed based on scan results combined with a specific blood marker (CA 19-9) above a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06389552 · HK inno.N Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇰🇷 KR

Who might be able to join this trial: - People who are 20 years of age or older at the time of signing the consent form - People who are planned to receive a chemotherapy treatment called FOLFIRINOX after surgery for pancreatic cancer - People who have a good general health and activity level, rated as 0 or 1 on a stan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06391892 · Elisabethinen Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2025
🇦🇹 AT

Who might be able to join this trial: - People who are willing to give their informed consent to take part in the trial - People who are over 18 years old - People who have pancreatic cancer that has not spread beyond the pancreas and where upfront surgery is planned Who may not be able to join: - People who have anot...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06405490 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People whose pancreatic cancer (specifically pancreatic ductal adenocarcinoma) has been confirmed through a tissue or cell sample test - People who have not yet received any systemic (whole-body) treatment for locally advanced or meta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06411691 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with pancreatic or colon cancer that has been confirmed through a tissue or cell sample (biopsy or lab test) - You have at least one tumor that can be safely biopsied more than once, and you are willing to have a tum...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06411795 · Masonic Cancer Center, University of Minnesota Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who are having a specific type of pancreatic surgery (called open pancreaticoduodenectomy) at the University of Minnesota Who may not be able to join: - People for whom a nerve-blocking procedure would be considered unsafe — for example, those with blood...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06412510 · Case Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People aged 65 or older - People diagnosed with advanced (Stage III or IV) epithelial ovarian cancer or fallopian tube cancer - People diagnosed with pancreatic cancer (Stage I, II, or III) who are receiving chemotherapy before surgery or other main treatment - People diagnosed w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06423326 · Emory University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) through a tissue or cell sample, where the tumour is considered removable by surgery or is on the borderline of being removable — this is assessed using detailed scan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06427239 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form - You are between 18 and 75 years old (male or female) - You have been diagnosed with advanced pancreatic cancer (either spread to other parts of the body or unable to be removed by surgery), and you have at least o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06427447 · Changhai Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by a pathology test - People whose pathology results show at least one of the following: cancer spread to nearby lymph n...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06427460 · Changhai Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old - People who have been diagnosed with a confirmed cancer of the lung, liver, pancreas, or retroperitoneal area (the space at the back of the abdomen) - People with metastatic cancer where the cancer has spread to only a limited number of si...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06435260 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People who are generally active and able to carry out daily activities with little or no limitation (confirmed by a doctor using a standard scale called ECOG, with a score of 0 or 1) - People whose tumor is located in the pancr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06447662 · Pfizer Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 19 January 2028
🇨🇳 CN Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (through tissue or cell testing) with an advanced, inoperable, and/or spreading or returning solid tumour cancer. - People who have a good general health and activity level, able to carry out everyday activities with little or no limitation (EC...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06451497 · Zumutor Biologics Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form. - People with an advanced or metastatic solid tumour (one that has spread or cannot be cured) that has stopped responding to standard treatments, or where standard treatments are not tolerated. Specific cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06453486 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2030
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with locally advanced pancreatic cancer (cancer confirmed by tissue or cell testing). - People whose pancreatic tumour measures less than 8.0 cm at its widest point at the time of treatment planning (final confirmation depends on meeting certain rad...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06454383 · City of Hope Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 13 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have given written consent to participate, or whose legally authorised representative has done so on their behalf (adults who are unable to consent themselves may be eligible if they have a caregiver who can ensure they take their medication as required). - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06454448 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People who have been confirmed through a biopsy or cell sample to have pancreatic cancer that started in the ductal lining of the pancreas, and whose cancer has spread to other parts of the body (stage IV) - People who have not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06472388 · AC Camargo Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 May 2026
🇧🇷 BR

**Who might be able to join this trial:** - People who have been confirmed by a tissue biopsy to have a slow-growing (Grade 1 or Grade 2) neuroendocrine tumour (NET) that started in the digestive system, pancreas, lungs, or an unknown location in the body. - People whose cancer has spread to other parts of the body, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06475326 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through a tissue or cell sample — a tissue sample is preferred - People whose cancer has been assessed by the tria...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06478225 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study. - You are between 18 and 75 years old (any gender). - Your doctors expect you to live for at least 3 more months. - You are generally well enough to carry out daily activities with little or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06479239 · University of Virginia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced, unresectable, or metastatic pancreatic cancer that is not suitable for curative treatment, confirmed by a tissue biopsy. - People who have received at least one round of chemotherapy (using gemcitabine, 5-fluorouracil/cap...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06483555 · UNC Lineberger Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of signing consent. - People who are in generally good functional condition, rated 0 or 1 on a standard oncology scale (meaning fully active or able to carry out light work). - People with a confirmed diagnosis of pancreatic adenocarcinoma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06487377 · Shanghai Pudong Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to sign a consent form to take part in the study - People aged 18 to 70 years old (inclusive), of any gender - People who have been diagnosed with advanced pancreatic cancer or colorectal cancer, whose cancer has not responded to — or who c...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06491472 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent and follow all study requirements and procedures. - People who have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), including a related type called adenosquamous carcino...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06494514 · Du Juan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with pancreatic cancer confirmed by a laboratory test of tissue or cell samples - People whose general health and ability to carry out daily activities meets a certain minimum level (a doctor will assess this using a standard scale called the ECOG s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06496373 · Ruijin Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender, who are willing and able to follow the study procedures as judged by the research team - People who have been diagnosed with a cancerous tumour of the pancreas through pathology testing, and who had surgery to remove the tumour between...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06499792 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇫🇷 FR

Who might be able to join this trial: - People aged 18 or older. - People who had planned surgery to remove part or all of the pancreas and duodenum (a section of the small intestine), with or without additional blood vessel or liver surgery performed through an open abdominal incision, at Strasbourg University Hospita...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06503497 · Zhejiang University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old (inclusive), of any gender. - People who have been diagnosed with a specific type of pancreatic cancer (pancreatic ductal adenocarcinoma or IPMN carcinosis) confirmed by laboratory testing of tissue or cells, and whose cancer has not r...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06505395 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any sex - People who have been diagnosed with an advanced gastroenteropancreatic neuroendocrine tumour (a type of tumour affecting the digestive system or pancreas), confirmed by tissue testing - People who have at least one measurable tumour that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06515587 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 75 years old (any gender) and are willing to sign a consent form after understanding what the trial involves - You are well enough to carry out basic daily activities, with an activity/health status score in the acceptable range (confirm with trial site) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06524973 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 May 2027
🇺🇸 US

**Who might be able to join this trial:** **For patients:** - The person must provide documented informed consent (or have a legally authorized representative do so) - The person must be 18 years of age or older - The person must have a performance status of ECOG 2 or below, meaning they are able to carry out some dai...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06526442 · Yu Shi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to give written consent to participate - People who are 18 years of age or older - People who have no history of cancer outside of the pancreas - People who did not have a bile duct drainage procedure before surgery - People who have confirmed panc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06531278 · Jiang Long Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to participate and have signed a consent form agreeing to take part in the study - People aged 18 to 75 years old (male or female) - People who have been diagnosed with pancreatic cancer that has spread to the liver, confirmed by a tissue sample (biops...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06532617 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 80, of any gender, who have signed a consent form to participate - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by laboratory testing of tissue - People whose pancreatic cancer has no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06538857 · CEBIOTEX Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇪🇸 ES

**Who might be able to join this trial:** - You must be 18 years old or older. - You must have been diagnosed with a specific type of pancreatic cancer (carcinoma, adenocarcinoma, or ductal adenocarcinoma) that is either locally advanced, resectable (able to be removed by surgery), or borderline resectable — confirmed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06539806 · Tanta University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 August 2026
🇪🇬 EG

**Who might be able to join this trial:** - People aged 50 or older who have been diagnosed with pancreatic cancer - People who have high blood pressure, with a reading of 140/90 mmHg or higher - People whose pancreatic cancer has been confirmed by laboratory testing of tissue samples, and whose cancer has either sprea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06541340 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic head cancer (either confirmed by tissue biopsy or agreed upon by a specialist medical team), who have yellowing of the skin caused by the tumour blocking the bile duct, and who are planned to have a major surgery to remove the a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06547736 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇳 CN

Who might be able to join this trial: - People who have chosen to take part voluntarily and have signed a consent form - Adults aged 18 to 75 years old, of any gender - People diagnosed with advanced pancreatic cancer (either spread to other parts of the body or unable to be removed by surgery), with at least one measu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06562192 · Novartis Pharmaceuticals Phase 1 · 10 countries Recruiting
Recruiting Phase 1 Est. completion 15 January 2031
🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇳🇱 NL🇪🇸 ES +2 more

Who might be able to join this trial: - People aged 18 or older - People with pancreatic cancer (PDAC) that has spread or cannot be surgically removed, and whose cancer has continued to grow after chemotherapy, or who were unable to tolerate or were not eligible for chemotherapy - People with non-small cell lung cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06564571 · Orlando Health, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who are already scheduled to have an endoscopic ultrasound examination (a procedure where a small camera with a sound-wave device is passed into the digestive tract to look at nearby organs) Who may not be able to join: - People under the a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06574373 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with a slow-growing, non-aggressive type of pancreatic cyst called an IPMN (intraductal papillary mucinous neoplasm) that is currently being monitored - People who have been diagnosed with a more serious form of IPMN, or a type of pancreatic can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06574620 · British Columbia Cancer Agency Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 years or older. - People who have been diagnosed with pancreatic cancer (PDAC) that has been assessed by tissue sample or imaging as removable by surgery, borderline removable, or locally advanced (spread within the area but not to distant parts of the body)....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06576115 · Barbara Ann Karmanos Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with advanced pancreatic cancer (adenocarcinoma type) that has spread to other parts of the body, confirmed by a biopsy or lab test. - You have at least one tumor that can be measured on a CT scan, MRI, or PET scan. - If you are a woman who could beco...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06577532 · Ruijin Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You must be 18 years of age or older at the time of signing the consent form - You have been diagnosed with an advanced solid tumor (such as pancreatic cancer or non-small cell lung cancer) that has been confirmed by a tissue or cell sample, and your cancer has gotten worse o...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06584227 · Liu Xiufeng Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 July 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old - People who have been confirmed through a tissue or cell sample to have pancreatic cancer that started in the ductal lining of the pancreas, and whose cancer cannot be removed by surgery and has either spread locally or to other parts of the body (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06585072 · Shanghai Changzheng Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who identify as Chinese (male or female) - People aged 18 years or older - People with pancreatic cancer who are planned to have pancreas surgery at the hospital running this trial - People who have agreed to take part in the Pancreatobiliary Surgery Cohort Study and have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06592989 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇨🇳 CN

Who might be able to join this trial: - People who fully understand the study and are willing to sign a consent form agreeing to take part - People aged 18 to 80 years old - People who have been diagnosed with pancreatic neuroendocrine tumours (any grade) through a tissue or cell sample, and whose condition has continu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06593431 · M.D. Anderson Cancer Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 29 June 2029
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older. - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by a tissue or cell sample. - People whose cancer has spread to a limited number of places in the body — between one and five sep...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06598007 · Crossignal Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are able to give voluntary, informed consent and are willing to follow all study procedures from start to finish. - People aged 18 or older (or the adult age as defined by local rules). - People with a cancer diagnosis confirmed by tissue or cell testing, where th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06598033 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form. - People aged 18 to 80 years old. - People whose general physical health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06600906 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older. - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed through a tissue or cell sample. - People whose cancer has spread to nearby areas or to other parts of the body. - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06601010 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with pancreatic cancer through laboratory testing and whose doctors have determined they need combination immunotherapy based on clinical guidelines - People who have signed and dated a consent form agreeing to take part in the trial - People who ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06601283 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 22 November 2026
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand the study and are willing to sign a written consent form. - People aged 18 to 80 years old. - People with a general health and activity level rated as fairly good (rated 0–2 on a standard scale used by doctors to measure how cancer affects daily...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06605404 · Paradigm Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2031
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older. - People with a confirmed solid tumour diagnosis (proven by biopsy or lab testing) that fits into one of the trial's specific cancer groups or the general "Mix of Solid Tumors" group. - People whose cancer is being treated with the aim of a cure, wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06605430 · HealthPartners Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of enrollment - People who have been diagnosed with pancreatic or colorectal cancer confirmed through a tissue or cell sample (note: neuroendocrine tumors of the pancreas or colon are not included) - People whose cancer is at an advanced s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06638866 · Changhai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇳 CN

Who might be able to join this trial: - People who are already scheduled for a routine chest and/or abdominal CT scan (without contrast dye) for a reason unrelated to the pancreas. Who may not be able to join: - People who have a history of pancreatic cancer. - People who have previously had surgery on the chest or ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06639724 · University of California, San Diego Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are able to understand and are willing to sign a consent form agreeing to take part in the study. - You are 18 years of age or older. - You are generally healthy enough to be active and care for yourself, with only minor limitations on physical activity (confirm with tri...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06648434 · Washington University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a lab test, who have not yet received any systemic treatment for advanced or spread disease. Tumors with mixed cell types are allowed if the pancreatic adenoc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06655233 · The Third Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 80 years old (male or female) - You have a growth or abnormal area in your pancreas that was seen on a scan (such as an ultrasound, MRI, CT, or PET-CT) and doctors strongly suspect it could be pancreatic cancer that needs a biopsy to help confirm the diagno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06659705 · Institut Curie Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 4 August 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with pancreatic cancer (PDAC) confirmed by a tissue or cell sample test - A recent CT scan and MRI (done within the last month) has shown that the cancer has not spread to other parts of the body - You are already enrolled in, or able to enroll in, a s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06666803 · IHU Strasbourg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older. - People who are scheduled for a procedure called echo-endoscopy (a scan using a camera and ultrasound inside the body) where a fine needle biopsy — taking a small tissue sample — is planned or being considered. - People where a pancreatic lesion (an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06673017 · PanTher Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - Imaging results that suggest borderline resectable or locally advanced pancreatic ductal adenocarcinoma (a type of pancreatic cancer), confirmed or to be confirmed through tissue or cell samples - A doctor has determined that a laparoscopy (a procedure to look inside the abd...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06693986 · Masonic Cancer Center, University of Minnesota Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 October 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer) that, based on scans (CT or MRI) and an internal ultrasound procedure, appears to be limited to the pancreas and nearby lymph nodes. - People who have had one previous round...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06694792 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with a condition called IPMN (a type of pancreatic cyst), whether or not they are having surgery for it - People who are willing to sign a consent form agreeing to take part in the study - For patients whose data is being collected...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06698458 · Alpha Tau Medical LTD. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇦 CA🇮🇱 IL🇺🇸 US

**Who might be able to join this trial:** - You have been newly diagnosed with pancreatic cancer that has either spread to nearby areas and cannot be removed by surgery (Group 1), or has spread to other parts of the body (Group 2), confirmed by a tissue or cell sample. - You are able to receive an initial course of ch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06705335 · Institut Bergonié Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with, or are suspected of having, pancreatic adenocarcinoma (a specific type of pancreatic cancer) based on scans or confirmed by tissue testing - People who are already scheduled (as part of their standard medical car...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06706700 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2025
🇮🇹 IT

Who might be able to join this trial: **Cohort A (people who have already had surgery):** - People who have been diagnosed with a type of pancreatic cyst called IPMN, confirmed by laboratory examination of tissue samples, with complete pathology results available (including cyst type, how abnormal the cells look, and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06714604 · Sahlgrenska University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2032
🇸🇪 SE

**Who might be able to join this trial:** - People diagnosed with borderline or locally advanced pancreatic cancer (a specific type called adenocarcinoma), based on recognised medical guidelines - People whose diagnosis has been confirmed by a tissue or cell sample, ideally taken using a procedure called an endoscopic...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06722911 · Zhejiang Provincial People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate - People aged 18 to 75 years old, of any gender - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by laboratory testing, had surgery t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06723236 · MacroGenics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of one of these cancer types that cannot be surgically removed and has spread or cannot be treated locally: non-small cell lung cancer (a type called adenocarcinoma), bile duct cancer (cholangiocarcinoma), colorectal cancer, or pancreati...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06725693 · Tianjin Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have a suspected, newly diagnosed, or previously treated cancer, supported by evidence such as scans, blood tests, or tissue reports - You are already scheduled to have a specific type of imaging scan called an Exendin 4 PET/CT scan - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06730009 · Medigen Biotechnology Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2029
🇹🇼 TW

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part. - Adults aged 18 or older at the time of giving consent, of any sex. - People who have had surgery to remove a pancreatic or bile duct tumour, where the tumour was classified as stage II or III before or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06736678 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a confirmed malignant tumour of the pancreatic ducts (confirmed by laboratory testing of tissue) - People with pancreatic cancer that can be surgically removed and are receiving chemotherapy and radiation before surgery, OR people with loc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06736717 · University of Kansas Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a written consent form agreeing to take part - Adults aged 18 or older, of any gender - People who are generally well enough to carry out normal daily activities with little or no limitation (this is measure...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06747481 · University of Las Palmas de Gran Canaria Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇪🇸 ES

Who might be able to join this trial: - People who have been diagnosed with a type of cancer called adenocarcinoma, confirmed through laboratory analysis of tissue. - People who have had surgery to remove the tumour. - People who had blood test results available before surgery that allow calculation of a specific immun...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06747845 · Abramson Cancer Center at Penn Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic adenocarcinoma (a type of pancreatic cancer) that has spread to other parts of the body, confirmed by a tissue or cell sample. - People who are 18 years of age or older. - People who are able to understand what the study involve...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06752811 · Shanghai Yizhong Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old (inclusive). - People with pancreatic cancer that has spread to other parts of the body, confirmed by a tissue or cell sample. - People who have not previously received any systemic treatment (such as chemotherapy, targeted therapy, or immu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06755359 · Alpha Tau Medical LTD. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced pancreatic adenocarcinoma, confirmed by a tissue or cell sample analysis - People whose tumor is in a location where the Alpha DaRT radiation seeds can be physically inserted - People whose tumor can be measured using stan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06756074 · Minia University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 April 2026
🇪🇬 EG

Who might be able to join this trial: - People who are scheduled to have a specific major surgery called a pancreaticoduodenectomy (a surgical procedure to remove part of the pancreas and surrounding structures) to treat cancer - People who are able to understand and sign a consent form agreeing to take part in the stu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06757244 · Hopital Foch Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 18 February 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with stage IV pancreatic cancer (adenocarcinoma type) confirmed by a tissue test, with cancer that has spread to other parts of the body - People who have not yet received any treatment for their stage IV pancreatic cancer (previous treatment g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06758544 · Guangdong Provincial People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part and have signed an approved consent form before any study-related procedures begin. - People aged 18 to 75 years old at the time of the screening visit. - People who have been clinically diagnosed with pancreatic cancer. - People with a good to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06760364 · Tianjin Medical University Cancer Institute and Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 24 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and sign a written consent form - People aged 18 to 70 years old, of any gender - People who have been diagnosed with advanced or spreading pancreatic cancer through laboratory tissue testing, and whose cancer has either stopped responding to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06761027 · Fujian Provincial Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years, of any gender - People who have been diagnosed with locally advanced or metastatic pancreatic cancer through a tissue or cell sample test - People who have not yet received any cancer treatment - People who have at least one tumour that can be measured...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06764134 · University Hospital Heidelberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇩🇪 DE

**Who might be able to join this trial:** - You are 18 years old or older. - You are able to understand what the study involves and what it means to take part. - You are willing and able to sign a written consent form agreeing to participate. - You are already scheduled to have surgery to remove part of your pancreas (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06767813 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed the consent form agreeing to join the study. - You are between 18 and 75 years old (inclusive) at the time of signing the consent form. - You have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06770439 · Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent and are willing and able to follow the trial's required visits and procedures. - People who have been confirmed by laboratory testing to have pancreatic adenocarcinoma (a specific type of pancreatic cancer) that cannot be surgically remo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06770452 · Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old (inclusive). - People with metastatic pancreatic cancer (cancer that has spread from the pancreatic ducts to other parts of the body) for one group (Arm A), or locally advanced pancreatic cancer (cancer that has grown but not spread far fro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06777030 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with pancreatic cancer - People who are 18 years of age or older - People who have given their informed consent to participate in the trial Who may not be able to join: - People who do not need an endoscopy with biopsy (tissue sample), or for whom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06782685 · Dai, Guanghai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old - People diagnosed with pancreatic cancer confirmed by a tissue or cell sample test - People whose cancer cannot be removed by surgery, as assessed by a specialist team and imaging scans - People whose cancer did not respond to a first round of trea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06782932 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - People who have been newly diagnosed with pancreatic cancer (a specific type called adenocarcinoma), confirmed by a biopsy. - The cancer must be considered removable by surgery, as assessed by the study team. - People who agree to have a tumor biopsy as part of the study. - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06789679 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form. - People who are 18 years old or older at the time of signing the consent form. - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma (includ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06800469 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with pancreatic cancer (specifically adenocarcinoma) that can be surgically removed, and where surgery is planned as the first treatment - People whose overall health and ability to tolerate anaesthesia has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06801899 · Insel Gruppe AG, University Hospital Bern Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇩🇪 DE🇨🇭 CH

**Who might be able to join this trial:** - Adults aged 18 or older who are scheduled to have a specific type of major abdominal surgery (called a Whipple procedure) for a suspected or confirmed removable tumour of the pancreas, the lower bile duct, or a particular type of tumour at the point where the bile duct meets...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06803771 · University Hospital Southampton NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2028
🇬🇧 GB

Who might be able to join this trial: - People who are between 50 and 84 years old at the time of joining (based on birth year, not birth month) - People who have been diagnosed with type 2 diabetes within the last 180 days (with a small flexibility window of 20 days), or whose blood sugar marker (HbA1c) test result is...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06807437 · SWOG Cancer Research Network Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer or a pancreatic growth that has the potential to become cancerous, confirmed by tissue sample or imaging. - People who have a planned surgical removal of the tail/left portion of the pancreas (distal pancreatectomy) sched...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06813079 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 17 February 2028
🇨🇦 CA

**Who might be able to join this trial:** - People aged 18 years or older - People who are willing and able to sign a written consent form before any screening takes place - People who have been diagnosed with advanced, inoperable pancreatic cancer of a specific type (ductal adenocarcinoma or acinar cell adenocarcinom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06816823 · Changhai Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2025
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 70 years old - People who have locally advanced, spread, or returned pancreatic cancer, where a specific protein called eGR1 is found at certain levels on their tumour cells (confirmed through lab testing of tumour tissue), and whose cancer has not resp...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06821503 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older. - People whose general physical fitness is rated at 0 or 1 on a standard oncology performance scale, meaning they are fully active or have only minor limitations on physical activity. - People who have at least one tumour that can be measured on a sc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06831136 · The University of Texas Health Science Center, Houston Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to follow the study schedule, including attending all visits, treatments, and follow-up appointments - People who have been diagnosed with pancreatic cancer (confirmed by biopsy) that has either spread to other parts of the body or cannot be s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06835569 · Alterome Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a solid tumour cancer (confirmed by laboratory testing of tissue) that has a specific gene change called a KRAS mutation, detected through an approved molecular test. - People whose cancer cannot be removed by surgery, or has spread to other pa...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06840067 · Gansu Wuwei Tumor Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old - People who have been diagnosed with locally advanced or spreading (stage III or IV) pancreatic cancer, confirmed through a tissue or cell sample test - People who have at least one tumour that can be measured on a scan, according to standard...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06842303 · Central Hospital, Nancy, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 June 2027
🇫🇷 FR

**Who might be able to join this trial:** - A CT scan has shown a diagnosis of pancreatic cancer that has not spread to other parts of the body, confirmed using a specific type of detailed CT scan of the chest, abdomen, and pelvis - The person is 18 years of age or older - The person is enrolled in, or covered by, the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06843551 · Benjamin Spieler Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2030
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory testing of tissue or cell samples - People whose cancer has tested negative for a marker called micr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06844422 · Shandong Cancer Hospital and Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 18 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - People with locally advanced pancreatic cancer that cannot be removed by surgery, confirmed by a tissue or cell sample test, as classified by a standard medical staging system - People aged between 18 and 80 years - People who have at least one pancreatic cancer lesion that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06849063 · Yu Shi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing and able to sign a written consent form to participate - You must be 18 years old or older - You must have no history of cancer outside of the pancreas - You must not have had any drainage procedure on your bile duct before surgery - You must have a confir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06850623 · EXACT Therapeutics AS Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 15 December 2026
🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Your doctors have determined that surgery is not currently a suitable option for you, and scans and biopsy results show that your pancreatic cancer cannot be removed by surgery or is on the borderline of being removable. - Your doctor believes you are well enough to receive a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06850753 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇳🇴 NO

**Who might be able to join this trial:** - People who have been confirmed through tissue testing to have cholangiocarcinoma (bile duct cancer), or who are strongly suspected to have it based on scans, internal camera examinations, and a raised blood marker called CA 19-9 above 100 U/L - People who have a specific typ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06852014 · Fundación Pública Andaluza para la Investigación de Málaga en Biomedic... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇪🇸 ES

**Who might be able to join this trial:** - People who are malnourished or at risk of malnutrition, have been diagnosed with cancer or tumours affecting the pancreas, the area around it, or the duodenum (the first part of the small intestine), and have had a specific type of surgery called a cephalic pancreaticoduodene...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06855485 · Asan Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2025
🇰🇷 KR

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with a fluid collection near the pancreas, specifically a pancreatic or peripancreatic pseudocyst, or a walled-off area of dead tissue that contains less than 30% solid material - People whose condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06861088 · Quercis Pharma AG Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with pancreatic adenocarcinoma (a type of pancreatic cancer) that has spread to other parts of the body or has grown into nearby tissues, confirmed by a tissue or cell sample. - People who are currently receiving, or are about to start, their first...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06861452 · EIR Biotherapies s.r.l. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 July 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with a confirmed type of pancreatic cancer called pancreatic ductal adenocarcinoma, specifically classified as "locally advanced" (meaning it has grown but has not spread to other parts of the body) - People whose cancer shows no signs of havin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06861543 · Peking Union Medical College Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who agree to follow the trial schedule and procedures, and have signed a consent form. - People who are 18 years of age or older at the time of signing the consent form, regardless of gender. - People with advanced, inoperable, or metastatic pancreatic cancer who have alre...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06868849 · Shanghai JMT-Bio Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 August 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older - People who are willing to take part voluntarily and sign a consent form - People who have a solid tumour cancer that has been confirmed through a tissue or cell sample, who are currently receiving or have completed cancer treatment, and whose cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06881992 · Rezolute Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇫🇷 FR🇳🇱 NL🇨🇭 CH🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are willing to give written consent to participate. - People who have been clinically diagnosed with a neuroendocrine tumor (a type of tumor that can affect hormone production) that is causing the body to produce too much insulin, leading to dange...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06895031 · Guangzhou JOYO Pharma Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have a solid tumour that has been confirmed by laboratory testing of tissue, and whose tumour has a specific gene change called a RAS mutation (identified through molecular/genetic testing) - People with a RAS mutation whose cancer has continued to grow or spread a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06897644 · Gruppo Oncologico del Nord-Ovest Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2029
🇮🇹 IT

**Who might be able to join this trial:** - People who are able and willing to sign a consent form and follow the study plan. - People who are 18 years of age or older. - People who have been diagnosed through a tissue or cell sample with pancreatic adenocarcinoma (a specific type of pancreatic cancer) that cannot be...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06898385 · Sun Yat-sen University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 27 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a consent form agreeing to participate, including agreeing to tests for certain genetic markers - Adults between 18 and 75 years old (inclusive), of any gender - People who have been diagnosed with pancreatic ductal adenocarcinoma (a s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06904378 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2028
🇺🇸 US

**Who might be able to join this trial:** - A tissue or cell sample has confirmed that the person has pancreatic cancer of the type called adenocarcinoma. - The cancer can be measured or tracked using standard imaging criteria (known as RECIST 1.1). - The person has already received one prior treatment for pancreatic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06906562 · Sameek Roychowdhury Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced or metastatic pancreatic cancer (of any cell type), confirmed through a tissue or cell sample test - People whose cancer has a specific genetic change — either an FGFR gene fusion/translocation or an activating FGFR mutation — con...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06914349 · University of Thessaly Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇬🇷 GR

Who might be able to join this trial: - You are 18 years of age or older - You are scheduled to have a planned surgery called a pancreaticoduodenectomy (a major operation to remove part of the pancreas and nearby structures) - You have signed a consent form agreeing to take part in the study Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06914674 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 14 and 80 years old - You have been diagnosed with an advanced form of a specific type of pancreatic tumor (called SPTP) that has been confirmed by a tissue test, and the tumor tests positive for certain hormone receptors (ER/PR+) - Your cancer cannot be fully...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06922591 · Tango Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing the consent form - Your general health and ability to carry out daily activities is rated at a good or mostly good level (what doctors call ECOG performance status 0 or 1 — confirm with trial site) - Your tumor has a spe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06935448 · University of Thessaly Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇬🇷 GR

Who might be able to join this trial: - People who are adults (18 years of age or older) - People who have been diagnosed with pancreatic cancer - People who are scheduled for planned (non-emergency) open pancreatic surgery Who may not be able to join: - People under 18 years of age - People requiring emergency pancre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06937996 · Englewood Hospital and Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2035
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People whose cancer has been found to be locally advanced and cannot be removed by surgery, confirmed by CT or MRI scan and a surgical assessment, after receiving standard chemotherapy with or without radiotherapy - People who have not had chemothera...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06941857 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People whose ability to carry out daily activities is rated at a high level (ECOG performance status of 0 or 1, meaning fully active or restricted only in physically strenuous activity) - People who have been diagnosed with pancreatic ductal adenocarcino...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06944106 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old. - People whose pancreatic cancer has been confirmed through a tissue or cell sample test (biopsy or similar). - People whose cancer is classified as "borderline resectable," meaning it may be possible to remove with surgery but is in a difficu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06944587 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇳🇴 NO

Who might be able to join this trial: - People diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that is either "borderline resectable" (on the edge of being removable by surgery) or "locally advanced" (has grown beyond the pancreas but has not spread to distant parts of the body) - People whose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06945978 · Benedito Mauro Rossi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with pancreatic cancer that has spread to other parts of the body (metastatic pancreatic ductal adenocarcinoma) - You are about to start a chemotherapy treatment called FOLFIRINOX - You are 18 years old or older - You are willing to take part in the st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06953193 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 January 2030
🇲🇽 MX

**Who might be able to join this trial:** - People who have given their written agreement to take part in the study. - People who are scheduled for a planned surgical procedure called a pancreatoduodenectomy (a major operation involving the pancreas and surrounding organs) at the National Institute of Medical Sciences...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06953999 · Akeso Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 14 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study. - You are between 18 and 75 years old (any gender). - You are generally well enough to carry out light activity and care for yourself, based on a standard health scale used in cancer care (con...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06958328 · NRG Oncology Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 21 October 2030
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - You must have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample - Your cancer must be locally advanced and not able to be removed by surgery, as determined...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06959615 · Jacobio Pharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a locally advanced, inoperable, or metastatic solid tumour cancer that has been confirmed by lab testing, and whose cancer shows a specific change in a gene called KRAS (either a mutation or an increase in copies of the gene). - People who are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06962267 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to join the study - You are between 18 and 75 years old (at the time of signing the consent form) - You have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06973564 · Jacobio Pharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form. - People who have a confirmed diagnosis of a locally advanced or metastatic solid tumour (a cancer that has spread or cannot be surgically removed to cure it). - People whose tumour has a specif...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06983743 · Erasca, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who are willing and able to sign a written consent form - People who have laboratory-confirmed documentation of their tumour type and any relevant genetic mutations before starting the study drug (where this applies to their specific group in...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06984562 · Fox Chase Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample test. - People whose pancreatic cancer has been determined to be locally advanced and cannot be removed by surgery, based on spec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06998940 · SWOG Cancer Research Network Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of pancreatic cancer called ductal adenocarcinoma, confirmed by laboratory testing of tumor tissue. - People whose tumor testing (done through a certified laboratory using a tissue sample — not a blood test) has shown the a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06999954 · Shwachman-Diamond Syndrome Alliance Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2088
🇺🇸 US

**Who might be able to join this trial:** - People of any age who have been formally diagnosed with Shwachman-Diamond Syndrome (SDS), either through genetic testing or based on clinical symptoms and signs. - People whose genetic testing shows changes (mutations) in specific genes linked to SDS, particularly the SBDS o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07006077 · Hangzhou Converd Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study. - You are a man or woman between 18 and 75 years old. - You have been diagnosed with advanced pancreatic cancer (confirmed by a tissue or cell sample) that has stopped responding to, or could...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07007832 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have a biliary stricture (a narrowing of the bile ducts) that doctors have not yet been able to diagnose as cancerous or non-cancerous - People between the ages of 18 and 90 years old - People who have already had a procedure called ERCP, during which a small tissue sa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07009119 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇪🇬 EG

**Who might be able to join this trial:** - People diagnosed with cancer of the pancreatic head, bile duct (cholangiocarcinoma), duodenum, or the ampulla (the area where the bile duct meets the small intestine) that doctors believe can be surgically removed with the goal of cure. - People whose cancer scans show no si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07022015 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 September 2026
🇪🇬 EG

**Who might be able to join this trial:** - You have a cancer in one of the following areas that can be surgically removed: the lower part of the bile duct, the area around where the bile duct meets the small intestine, the small intestine (duodenum), or the head of the pancreas. - There is no sign that the cancer has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07024615 · Astellas Pharma Global Development, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with localised pancreatic adenocarcinoma (a specific type of pancreatic cancer) through laboratory testing, where a specialist team has determined the cancer can be surgically removed, and who have not received any prior treatment for this canc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07030283 · University of Colorado, Denver Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a consent form and follow all study requirements for the full duration of the trial. - People aged 18 years or older. - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed by...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07030348 · Do Hyun Park Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** This trial has two groups. People may be considered for the **pancreatic cancer group** if they meet all of the following: - The person is at least 19 years old. - The person has already signed informed consent for a planned upper endoscopy, endoscopic ultrasound, or ERCP pro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07033689 · SONIRE Therapeutics Inc. Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have signed an ethics board-approved consent form agreeing to take part in the study - Adults aged 18 or older (men and women) - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by a tissue or cell sa...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07034339 · First Affiliated Hospital of Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Healthy people who do not have any known liver, gallbladder, or pancreas conditions (whether cancerous or non-cancerous) - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) for the first time - People who have a non-ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07040228 · Junjie Hang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who fully understand the study, choose to take part voluntarily, and sign a consent form - People aged 18 to 80 years old - People who have been diagnosed with pancreatic cancer that cannot be surgically removed or has spread to other parts of the body, confirmed by a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07043270 · Dartmouth-Hitchcock Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with borderline resectable pancreatic ductal adenocarcinoma (a specific stage of pancreatic cancer), where the determination of surgical eligibility has been made by the surgical oncology team at the Dar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07044453 · University Hospital, Rouen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2030
🇫🇷 FR

**Who might be able to join this trial:** - People who have had surgery to remove pancreatic cancer (confirmed by laboratory testing of the removed tissue), where the surgery aimed to remove all of the cancer, and who have already completed 3 months of pre-surgery chemotherapy using a regimen called mFOLFIRINOX — incl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07045571 · Yingbin Liu, MD, PhD, FACS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been found to have a growth or mass in the pancreas through imaging scans, where a malignant (cancerous) tumour is strongly suspected, and who are planned to have surgery or a tissue sample (biopsy) taken for further...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07054879 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC), confirmed through laboratory testing of tissue or cell samples - People whose cancer has not spread to distant par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07066995 · Essen Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Doctors expect you to live for at least 3 more months. - You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that has spread or cannot be removed by surgery, and you have already tried standard chemotherapy treatments (such as gemcitabine/n...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07079228 · Qilu Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily and have signed a consent form agreeing to participate in the study - People who are generally well enough to carry out daily activities with little or no limitation (based on a standard medical fitness scale scored 0 or 1) - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07080021 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any gender). - You have been diagnosed with pancreatic cancer confirmed by a tissue sample (biopsy), and your cancer falls into one of three categories: high-risk but potentially removable by surgery, borderline removable by surgery, or lo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07081360 · Minia University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 20 July 2028
🇪🇬 EG

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic head cancer or a nearby tumour (called periampullary carcinoma), confirmed by a tissue or cell sample taken during an ultrasound-guided procedure. - People whose cancer is clearly removable by surgery, meaning the tumour has not...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07087054 · Crinetics Pharmaceuticals Inc. Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 1 August 2027
🇦🇷 AR🇧🇷 BR🇨🇱 CL🇨🇴 CO🇫🇷 FR🇲🇽 MX🇪🇸 ES🇬🇧 GB +1 more

**Who might be able to join this trial:** - You are 18 years of age or older at the time of screening - You are willing and able to follow all study procedures, including completing a study diary at least 70% of the time over a 2-week period - You have been diagnosed with carcinoid syndrome that needs medical treatmen...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07089940 · OHSU Knight Cancer Institute Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a consent form before any study procedures begin - People who are 18 years of age or older at the time of signing consent - People whose general health and ability to carry out daily activities falls within a certain range, as measured...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07090499 · Pfizer Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 8 July 2028
🇨🇦 CA Puerto Rico🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas - Your cancer can be measured on scans or tests - You are generally well enough to carry out daily activities with little or no limitati...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07094204 · Astellas Pharma Inc Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 30 November 2028
🇫🇷 FR🇯🇵 JP🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of a solid tumour cancer that has either spread to other parts of the body or cannot be surgically removed, and whose tumour has a specific gene change (called a KRAS mutation — G12V, G12D, G12C, G12R, G12A, or G13D) or a high number of...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07098598 · Turku University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2026
🇫🇮 FI

Who might be able to join this trial: - People with a suspected new or returning pancreatic cancer diagnosis. - People aged 18 to 85 years old, either male or female. - People with a general health performance level rated 0 to 2 on the WHO scale, meaning they are able to carry out at least some daily activities (confir...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07101679 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by tissue testing and imaging scans, and a specialist team has decided the tumor cannot be surgically removed - You have not yet received any treatment for yo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07110064 · Du Juan Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older who have a reasonable level of physical functioning (able to carry out basic daily activities) and are expected to live for at least 3 months. - People who have been diagnosed with advanced, metastatic pancreatic cancer confirmed through laboratory te...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07114315 · Akeso Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to sign a written consent form agreeing to take part. - People who are expected to live for at least 3 months. - People who have a good general level of physical functioning, rated 0 or 1 on a standard oncology scale (meaning fully active or able t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07114861 · New Cancer Cure-Bio Co.,Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 September 2028
🇰🇷 KR

**Who might be able to join this trial:** - People aged 19 to 75 years old at the time of signing consent forms - People whose pancreatic cancer has been confirmed by laboratory testing of tissue or cells, and whose cancer cannot be surgically removed, has spread locally, or has spread to other parts of the body, and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07114939 · Abramson Cancer Center at Penn Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a pancreatic neuroendocrine tumor that has spread to other parts of the body or cannot be surgically removed, and is classified as grade 1, grade 2, or grade 3 - People who have at least one tumor or lesion measuri...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07117032 · Case Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer (confirmed by a tissue or cell sample) that has spread or cannot be surgically removed, and your doctor thinks this radiation treatment is appropriate for you. - You are over 18 years old. - You are well enough to carry out some daily acti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07124611 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been newly diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC) that has not spread beyond the pancreas area - You are being seen at Ohio State University Wexner Medical Center-Comprehen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07126158 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced pancreatic cancer (a specific type called adenocarcinoma) that has been confirmed by a lab test, and whose cancer is considered either "borderline resectable" (possibly removable by surgery) or "locally advanced" (not able to be r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07132541 · Minia University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 25 August 2026
🇪🇬 EG

**Who might be able to join this trial:** - People who are having a specific type of pancreatic surgery (called a pancreaticoduodenectomy) with the goal of fully removing a cancerous growth, in line with standard medical guidelines. - People whose pancreas tissue has a soft texture (as assessed by the surgical team). -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07139236 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years of age or older. - You are scheduled for a planned (non-emergency) surgical procedure to remove part of the pancreas and surrounding structures, due to a condition affecting the head of the pancreas or nearby area. - Your condition may include pancreatic canc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07148128 · Auricula Biosciences Inc. Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇦 CA🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - People diagnosed with an advanced solid tumour that has a specific gene change called a KRAS mutation, in one of these cancer types: pancreatic cancer (ductal adenocarcinoma), colorectal cancer, non-small cell lung cancer, platinum-resistant serous ovarian cancer, bile duct cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07148830 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇪🇬 EG

**Who might be able to join this trial:** - People aged 18 or older - People who are scheduled to have a specific type of pancreatic surgery called a pancreaticoduodenectomy, which involves removing part of the pancreas, small intestine, and surrounding tissue - People who have been confirmed through a biopsy (tissue...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07155525 · Minia University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 September 2028
🇪🇬 EG

**Who might be able to join this trial:** - People who are scheduled for a planned (non-emergency) surgical procedure called a pancreaticoduodenectomy (a major operation to remove part of the pancreas) for a cancerous growth. - People whose pancreas is found during surgery to have a soft, delicate texture, as confirmed...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07157033 · Xerient Pharma Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma), confirmed by a tissue or cell sample test - People whose cancer has been reviewed by a specialist surgical team and found to be either not removable by surgery due to how the tumou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07157605 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 8 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇨🇳 CN🇬🇷 GR🇮🇹 IT🇯🇵 JP🇳🇱 NL🇳🇴 NO🇪🇸 ES🇸🇪 SE

Who might be able to join this trial: - Adults aged 18 or older who are having surgery (either open surgery or a minimally invasive approach using a robot or small incisions) to remove the left part of the pancreas and the spleen at the same time, for a type of pancreatic cancer (called PDAC) that is located on the lef...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07166601 · EMD Serono Research & Development Institute, Inc. Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 23 February 2029
🇨🇦 CA🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - (Part 1 – M0324 alone) People with certain advanced or spreading solid tumours that produce high levels of a protein called MUC-1, where standard treatments have stopped working, caused intolerable side effects, or where the treating doctor considers no standard treatment to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07167264 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old who are willing to voluntarily sign a consent form to take part in the study - People who have been diagnosed with pancreatic cancer based on clinical and pathological (tissue) testing, matching the standard medical classification for t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07172802 · GI Innovation, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 18 or older at the time of screening (or 19 or older, depending on local regulations) - People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements - People whose cancer can be measured on scans, according to a standa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07183280 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2040
🇨🇳 CN

Who might be able to join this trial: - People of any age, gender, or physical condition may be considered - People who have had a solid pseudopapillary neoplasm (a type of pancreatic tumour) confirmed through laboratory testing of tissue or cell samples - People who are able and willing to attend follow-up appointment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07186296 · EXoPERT Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

Who might be able to join this trial: - People aged 45 years or older who have been diagnosed with, or are suspected to have, a primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on scans, blood tests, endoscopy, or tissue/cell findings. - People whose blood sample was collected before receiving any...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07189195 · University of California, Davis Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 7 November 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have a solid tumour that has spread or cannot be surgically removed, confirmed by a tissue or laboratory test, and for which standard treatments have stopped working or could not be...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07198659 · The First Affiliated Hospital of Air Force Medicial University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 14 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years - People who are willing and able to sign a consent form agreeing to take part - People who have been diagnosed with pancreatic cancer that cannot be surgically removed, confirmed by a tissue sample test - People who have already tried standard firs...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07199764 · University of Pennsylvania Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who are able to understand what the study involves and are willing to sign a written consent form agreeing to take part - People who have been confirmed by a tissue or cell sample test to have pancreatic adenocarcinoma (a type of pancreatic c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07206355 · University of Nottingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇬🇧 GB

Who might be able to join this trial: - People aged 16 years or older - People who are able to give their own consent to take part in a research study - People who are already receiving standard medical care at Nottingham University Hospitals NHS Trust (NUH) for the investigation or treatment of a suspected narrowing o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07214298 · Roswell Park Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer (specifically pancreatic ductal adenocarcinoma) that has spread to other parts of the body, confirmed by a laboratory test on a tissue or cell sample. - People aged 18 or older. - People who are generally able to carry ou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07223047 · Bristol-Myers Squibb Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 13 October 2028
🇨🇦 CA🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a locally advanced, inoperable, or spreading (metastatic) solid tumour cancer that has a specific gene change called a KRAS mutation or amplification, confirmed by laboratory testing of tumour tissue. - People joining the specific group called...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07226154 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed through laboratory testing of tissue samples. - People who received chemotherapy (using either a regimen called FOLFIRINOX or a combination of Gemcitabi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07226856 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have had their pancreatic cancer confirmed by a tissue sample (biopsy), specifically a type called pancreatic adenocarcinoma - People whose cancer has spread to other parts of the body (metastatic) or has come back (recurrent) at the time...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07229768 · Yan Xing Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older with advanced, spreading, or inoperable solid tumours that have been confirmed by laboratory testing of tumour tissue or cells, and whose cancer has not responded to standard treatments, has no standard treatment options available, or who have chosen...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07230509 · Minia University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇪🇬 EG

**Who might be able to join this trial:** - You are scheduled to have a specific type of pancreas surgery (called a pancreaticoduodenectomy) with the goal of curing a cancerous growth, following standard medical guidelines. - Your pancreas tissue has a soft texture (confirmed during surgery). - The main tube inside you...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07232810 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇪🇬 EG

Who might be able to join this trial: - People aged 18 or older - People who are scheduled to have a specific type of pancreatic surgery called a pancreaticoduodenectomy, which involves removing part of the pancreas and surrounding tissue - People who have been diagnosed with pancreatic cancer in the head of the pancre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07235930 · Zhejiang Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who agree to take part and sign a consent form voluntarily - People aged 18 to 75 years old at the time of signing the consent form, of any gender - People who have been confirmed through tissue or cell testing to have pancreatic ductal adenocarcinoma (a specific type...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07236177 · Poitiers University Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 3 February 2028
🇫🇷 FR

Who might be able to join this trial: - People who have been definitively diagnosed with localised breast cancer that has not yet been treated, and who have been referred for surgery as their first treatment (Group 1) - People who have been definitively diagnosed with localised lung cancer that has not yet been treated...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07238283 · Jiangsu HengRui Medicine Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2028
🇨🇳 CN

Who might be able to join this trial: - People whose general health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (this is measured using a standard scale called ECOG, scores 0 or 1) - People with pancreatic cancer that has been confirmed through...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07241663 · Azienda Ospedaliera di Padova Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who are older than 18 years of age - People who are able to give their informed consent to participate - People whose cancer has been confirmed by laboratory testing to be pancreatic adenocarcinoma (a specific type of pancreatic cancer) - People whose pancreatic cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07243262 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 or older - People who have been referred by a GP or primary care doctor under urgent suspected cancer referral guidelines for a possible pancreatic cancer, or who have been referred directly to a pancreatic cancer specialist team Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07249775 · H. Lee Moffitt Cancer Center and Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older - You have been diagnosed with a type of pancreatic cancer (such as pancreatic ductal adenocarcinoma or similar), either confirmed by a tissue or cell sample, or strongly suspected and expected to be confirmed early in the study period - Your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07252232 · Revolution Medicines, Inc. Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 10 May 2029
🇫🇷 FR🇮🇹 IT🇯🇵 JP Puerto Rico🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - People who are at least 18 years old and have agreed to take part by signing a consent form - People whose general health and ability to carry out daily activities meets a certain level, known as an ECOG score of 0 or 1 — meaning fully active or restricted in strenuous activity o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07254091 · Northwell Health Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People of any sex, gender, race, or ethnic background are welcome to be considered - People who have a suspicious or confirmed pancreatic lesion (abnormal growth or area) for which a surgeon has determined that surgery is needed, eit...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07255404 · BioNTech SE Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with metastatic pancreatic ductal adenocarcinoma (a type of pancreatic cancer that has spread), confirmed through a tissue or cell sample, which must be provided during the screening period. - People who have not previously received systemic (whole-...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07257523 · Yonsei University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with pancreatic cancer that has been confirmed by a tissue sample (biopsy), and the cancer has not spread to distant parts of the body - You are not able to have surgery or standard chemotherapy — either because of your general health or frailty level,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07259317 · Corcept Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - You have signed and dated a consent form before any screening takes place - You have been diagnosed with pancreatic cancer (specifically pancreatic adenocarcinoma) confirmed by a tissue or cell sample - Your cancer was first diagnosed as having spread (metastatic) no more th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07261631 · Novartis Pharmaceuticals Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 9 May 2029
🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇱 IL🇸🇬 SG

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with one of the following cancers that cannot be surgically removed and has either spread locally or to other parts of the body: pancreatic cancer, non-small cell lung cancer, hormone receptor-positive/HER2-negative breast cancer (d...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07262567 · Genfleet Therapeutics (Shanghai) Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and agree to sign a consent form - People aged 18 to 80 years old (inclusive) at the time of signing the consent form - People who have been diagnosed through laboratory testing with pancreatic cancer (specifically the type that starts in t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07269626 · Samsung Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇰🇷 KR

Who might be able to join this trial: - You are 19 years of age or older. - You are able to carry out daily activities, with or without some limitations (your doctor will assess your general fitness level using a standard scale). - You have been diagnosed with a specific type of pancreatic cancer called pancreatic duct...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07272187 · Herlev Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2040
🇩🇰 DK

**Who might be able to join this trial:** - You have one or more growths or lesions that can be treated using a procedure called EUS-RFA (a type of internal heat treatment guided by ultrasound) - You have a type of pancreatic tumour called an insulinoma that is 25mm or smaller, confirmed by a 72-hour fasting test, ima...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07273409 · Uppsala University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2033
🇸🇪 SE

Who might be able to join this trial: - People diagnosed with stage 4 pancreatic neuroendocrine tumour (a specific type of tumour in the pancreas), confirmed by a CT scan or PET/CT scan - People whose tumour has been confirmed as a low-to-intermediate grade pancreatic neuroendocrine tumour (Grade 1 or 2) through a tiss...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07283705 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2029
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older. - People whose tumour testing (using a method called NGS) has confirmed a specific gene deletion called "homozygous MTAP deletion," detected from tissue collected within the past 6 months or from a blood sample. - People with a confirmed diagnosis of pan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07296341 · Shanghai Hengrui Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old (inclusive), of any gender, who are able to sign a consent form - People who are largely able to carry out daily activities with little or no restriction (a doctor will assess this using a standard scale called ECOG, with a score of 0...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07300150 · PAQ Therapeutics, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 18 October 2028
🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with an advanced or spreading solid tumour cancer, confirmed through a biopsy or cell sample test. - Your cancer has a specific gene change called a KRAS mutation, or a gene variation called wild-type KRAS amplifica...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07301814 · Union Hospital, Tongji Medical College, Huazhong University of Science... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - A person or their legal representative must be able to sign and date a consent form agreeing to take part. - Participants must be willing to follow the study procedures and take part in the full research process. - Adults aged 18 to 70 years, of any gender, including both pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07306286 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have been diagnosed with pancreatic cancer (specifically the type that starts in the lining of the pancreatic ducts), confirmed by laboratory testing, and whose cancer has been classified as locally advanced (not yet spread to o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07307664 · Josh Peterson Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - Healthcare team members who work in oncology care, such as oncologists, advanced practice providers, or nurse navigators, who care for adult patients with breast cancer, pancreatic cancer, or colorectal cancer Who may not be able to join: - Healthcare providers who are not part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07312422 · Zhejiang Provincial People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People whose general health and ability to carry out daily activities falls within a certain range, measured by a standard medical scoring tool called the ECOG scale (scores 0 or 1 indicate being fully active or having only minor limit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07319416 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇮🇹 IT

Who might be able to join this trial: - People aged 18 or older. - People who have been diagnosed through a tissue biopsy with a type of tumour called a gastroenteropancreatic neuroendocrine tumour (GEP-NET) that cannot be removed by surgery, is a specific grade (G2 or G3), and has a particular growth marker (Ki67) mea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07324096 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 March 2029
🇺🇸 US

Who might be able to join this trial: - People who are aged between 50 and 85 years old - People who have been newly diagnosed with diabetes based on blood sugar test results, where the diagnosis was made within the last 180 days (about 6 months) before joining the trial - People whose diabetes diagnosis, combined with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07328607 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2028
🇪🇬 EG

Who might be able to join this trial: - People aged 18 years or older. - People who have a confirmed or suspected tumour in one of these areas: the head of the pancreas, the ampulla (where the bile duct meets the small intestine), the lower part of the bile duct, the duodenum (upper small intestine), or people with a p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07349537 · Revolution Medicines, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** - You are at least 18 years old and are willing to give your consent to take part - You are relatively active and able to carry out daily activities with little to no limitation (this is measured on a standard scale called ECOG — confirm with trial site if unsure where you fall...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07353645 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years who are generally well enough to carry out daily activities with little to no limitation (confirmed by a doctor's assessment scale called ECOG 0–1). - People who have been diagnosed with colorectal cancer (bowel cancer) or pancreatic cancer confirm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07396662 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2034
🇹🇼 TW

Who might be able to join this trial: - People who are scheduled to have surgery to remove part or all of the pancreas (called a pancreatectomy) Who may not be able to join: - People who are younger than 20 years old or older than 75 years old - People who are pregnant Important: Always verify eligibility with the tr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07407231 · Institute of Oncology Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2024
🇸🇮 SI

Who might be able to join this trial: - You must be 18 years old or older - You have been diagnosed with pancreatic cancer that has grown locally and cannot be removed by surgery - You have already received chemotherapy as your first treatment, followed by a precise, targeted type of radiation therapy called SBRT, at o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07408505 · Shandong Cancer Hospital and Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed through a tissue or cell sample to have locally advanced or metastatic pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer). - People who have not yet received any systemic (whole-body) anti-cancer treatment for their cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07409272 · Astellas Pharma Global Development, Inc. Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 31 August 2029
🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with metastatic pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer that has spread), confirmed by a tissue test, and whose tumour has a specific genetic change called KRAS G12D mutation. - People for whom surgery to remove t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07425483 · Changhai Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old - People who have locally advanced, spreading, or returning pancreatic cancer, where a specific protein called eGR1 has been found at certain levels on the cancer cells through laboratory testing, and whose cancer has not responded to stand...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07429851 · European Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with a well-differentiated high-grade neuroendocrine tumour, confirmed by a specialist pathologist who focuses on this type of cancer, with a specific cell growth rate marker (Ki-67) above 20% based on 2022 World Health Organization standards. - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07436312 · Gustave Roussy, Cancer Campus, Grand Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who have been identified as having an increased risk of certain cancers, as defined by the Interception program - People whose baseline WCRF (World Cancer Research Fund) lifestyle score was 5 or lower when they entered the Interception progr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07436741 · Tianjin Medical University Cancer Institute and Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with high-risk or borderline resectable pancreatic cancer, confirmed through a tissue or cell sample test - People aged 18 to 75 years old (inclusive) - People who do not carry mutations in the BRCA1, BRCA2, or PALB2 genes - People who have not...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07438106 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed by a tissue or cell sample - People whose cancer imaging shows the disease is locally advanced — meaning it has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07445386 · Ankara Etlik City Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 August 2026
Turkey (Türkiye)

Who might be able to join this trial: - People experiencing severe abdominal pain (rated more than 6 out of 10 on a pain scale) caused by cancer in the upper abdominal organs, such as stomach, pancreatic, or liver cancer. - People whose pain has not been adequately controlled with standard pain management treatments....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07450859 · BicycleTx Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old at the time of signing the consent form - People whose cancer can be measured on scans, as defined by standard medical criteria (RECIST v1.1) - People with a general health and activity level rated as 0 or 1 on a standard scale used by do...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07463872 · Huazhong University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People whose ultrasound scan results (a type of internal imaging called EUS) show cyst-like growths on the pancreas - People whose pancreatic cysts are classified as mucinous types, such as mucinous cystic neoplasm (MCN) or intraductal papillary mucinous neoplasm (IPMN) (conf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07478185 · University of Massachusetts, Worcester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC) - People who are planned to receive chemotherapy before surgery to remove the cancer - People who have been assessed by a doctor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07480928 · Beijing Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 February 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old at the time of giving consent to participate. - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed through laboratory testing of tissue or cell samples. - People whose cancer cannot...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07481383 · Continuity Biosciences, LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are generally well enough to carry out daily activities with little to no limitation (as measured by a standard medical scale called the ECOG scale, with a score of 0 or 1). - People who have been diagnosed with pancreatic cancer that has not spread to other parts...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07483983 · Gustave Roussy, Cancer Campus, Grand Paris Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with either locally advanced (cannot be surgically removed) or metastatic non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC), confirmed by tissue testing, and whose cancer has a specific gene change called...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07491445 · Revolution Medicines, Inc. Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - People who are at least 18 years old and have agreed to take part by signing a consent form - People whose general health and ability to carry out daily activities meets a specific standard (a score of 0 or 1 on a scale doctors use to measure this) - People whose cancer has been...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07493421 · Unidade Local de Saúde São João Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇨🇳 CN🇵🇹 PT

Who might be able to join this trial: - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer) - People whose cancer has spread to the lining of the abdomen (peritoneal metastasis), confirmed through a tissue sample examination - People whose cancer has not spread to other...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07504471 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have been diagnosed with pancreatic cancer (specifically the type that starts in the lining of the pancreatic ducts) that has spread to the liver - People whose general physical functioning falls within a certain range, meaning...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07505797 · iSono Health, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study - You are able to commit to completing all parts of the study and be available for its full duration - You are female and between 18 and 94 years old (inclusive) - You have recently received a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07529483 · Ohio State University Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who are older than 18 years of age - People who have been diagnosed with a pancreatic cyst (a fluid-filled growth on the pancreas) confirmed through specialist procedures that examine the cyst using ultrasound, fluid sampling, or tissue analysis - People whose pancreatic c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07532590 · Casa di Cura Dott. Pederzoli Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇮🇹 IT

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with pancreatic cancer, confirmed by a laboratory tissue or cell test - People who have access to a smartphone or tablet with an internet connection, and either have basic ability to use digital devices or have a caregiver who can a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07536087 · Institute for Clinical and Experimental Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇿 CZ

**Who might be able to join this trial:** - A team of medical specialists has agreed that EUS-guided radiofrequency ablation (a procedure that uses heat to treat a lesion) is the right treatment for you (confirm with trial site) - You are able to understand and agree to take part in the study - You have a cyst in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07542002 · Ningbo Medical Center Lihuili Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People who have been confirmed by laboratory testing (tissue or cell sample) to have pancreatic cancer that started in the ductal lining of the pancreas, and whose cancer has been assessed by a specialist team as either removable b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07542041 · ARTIDIS AG Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who are able to understand the study and are willing to sign a written consent form - People who have a suspicious pancreatic lesion that their doctor has determined needs a fine needle biopsy and can be safely reached for that procedure Wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07554560 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with either pancreatic ductal adenocarcinoma (a type of pancreatic cancer) or a pancreatic neuroendocrine tumor (another type of pancreatic tumor) - People whose doctors estimate they have a life expectancy of 4 months or more...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07557849 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇨🇳 CN

Who might be able to join this trial: - People of any age, gender, or physical condition level may be considered. - People who have been diagnosed with pancreatic adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory testing of tissue or cell samples. - People whose cancer has been tested...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07560540 · University of Veterinary and Animal Sciences, Lahore - Pakistan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with cancer in one of these areas: the lower part of the bile duct, the head of the pancreas, the area around where the bile duct meets the small intestine (periampullary), or the duodenum (the first part of the small intestine) - People who are alr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07561814 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2029
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years old or older. - You must have been diagnosed with pancreatic cancer, confirmed through a tissue or cell sample test. - Your medical records at the participating hospital must include CT scan images taken before and after surgery, along with related medical in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07575191 · Smartwise Sweden AB Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇸🇪 SE

**Who might be able to join this trial:** - You are 18 years of age or older. - You have been diagnosed with locally advanced pancreatic cancer, confirmed by a tissue sample (biopsy). - You have been receiving chemotherapy through an IV for at least six months. - You are generally well enough to carry out daily activi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07586813 · Peking University People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have previously been diagnosed with a solid tumour in the digestive system, such as cancer of the gastrointestinal tract, pancreas, or colon and rectum - People whose cancer has gone into complete remission after chemother...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07589569 · Shandong Suncadia Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have given their informed consent before the study begins - People aged 18 to 75 years old (inclusive), of any gender - People who have been diagnosed with locally advanced, unresectable (cannot be removed by surgery), recurrent, or metastatic pancreatic cancer co...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07591571 · Loma Linda University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People between 18 and 90 years old - People who speak English or Spanish - People who have been diagnosed with a specific type of pancreatic cancer (pancreatic adenocarcinoma) for the first time, or who have a growth in the pancreas seen on a CT or MRI scan that doctors suspect m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07595172 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years, of any gender. - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed through a tissue biopsy or sample. - People whose pancreatic cancer has not been treated before, is locally...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07595835 · M.R. Meijerink Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with locally advanced pancreatic cancer that has grown into nearby blood vessels in a significant way (based on specific medical measurements — confirm with trial site) - Your cancer has not grown (has stayed stable...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07597772 · SmartNuclide Biopharma Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You are able to make your own decisions, are willing to take part voluntarily, and have signed the consent form for the study - You have been diagnosed with pancreatic cancer and your tumour can be tested for a protein called...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07605819 · Cosomil, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇯🇵 JP

**Who might be able to join this trial:** - Adults who do not currently have any symptoms and are attending a health facility for a routine check-up or a scheduled cancer screening (or both) - People who are able to understand what the study involves and are willing to sign a consent form before taking part **Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07612046 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 May 2028
🇺🇸 US

Who might be able to join this trial: - People who have two close blood relatives (such as a parent, sibling, or child) who have had pancreatic cancer, where at least one of those relatives is a direct (first-degree) relative of the person being considered - People who carry a harmful change (mutation) in one of these...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07619391 · Ohio State University Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with pancreatic adenocarcinoma (a type of pancreatic cancer) and are currently receiving treatment or are planning to start treatment within the next 30 days - People who speak English - People who have access to a sm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07621718 · Revolution Medicines, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2028
🇺🇸 US

Who might be able to join this trial: - You are at least 18 years old and have agreed to take part by signing a consent form. - Your general health and ability to carry out daily activities is rated as good or fully active (confirm with trial site for exact rating details). - Your cancer has been confirmed through a ti...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07627711 · Beijing Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 April 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years at the time of giving consent to participate. - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer), confirmed through laboratory testing of tissue or cell samples. - People whose cancer cannot be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07629609 · Barbara Malene Fischer Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇩🇰 DK

**Who might be able to join this trial:** **Group A (suspected pancreatic cancer):** - You are a man or woman aged 18 or older - Scans suggest you may have pancreatic cancer, though it has not necessarily been confirmed by biopsy - Your CT, MRI, or PET/CT scan, reviewed by a specialist medical team, shows no signs tha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07629960 · Blueprint Medicines Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with metastatic pancreatic cancer, non-small cell lung cancer, or colorectal cancer that has been confirmed by a pathology test to have a specific type of gene change called a KRAS mutation (one of the following: G12C, G12D, G12V, G12A, G12S, or G13...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07630961 · Novartis Pharmaceuticals Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 16 January 2028
🇯🇵 JP

**Who might be able to join this trial:** - You must be willing and able to sign a consent form before taking part in the study. - You must be 18 years of age or older. - You must be well enough to carry out some daily activities — not completely disabled by your illness (confirm with trial site regarding specific fit...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07632118 · Tianjin Medical University Cancer Institute and Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2029
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily and sign a consent form agreeing to participate in the study - People aged 18 to 75 years old, of any gender - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07636382 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with cancer (confirmed by a lab test) that has spread or cannot be surgically removed, and your doctor believes a specific type of focused radiation treatment to the celiac plexus (a nerve cluster in the abdomen) is appropriate for you. - You are older...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07647250 · University of Illinois at Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2031
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with pancreatic cancer that the treating medical team considers potentially removable by surgery - People who are planned to receive, or are already receiving, chemotherapy before surgery - People who ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07649928 · Ruijin Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have a tumor tissue sample available — either recently collected or stored within the past 5 years — that can be tested during the screening process - People who have been diagnosed with an advanced solid tumor (confirmed t...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07651358 · OHSU Knight Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of enrollment - People who have been diagnosed with stage I, II, or III pancreatic cancer - People who are scheduled to receive chemotherapy before surgery (called neoadjuvant chemotherapy) at Oregon Health & Science Univers...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07656571 · Alexandria University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years of age or older. - Your body mass index (BMI) is 40 or below (a measure of weight relative to height). - Scans have confirmed you have one or more growths on the middle or left part of your pancreas that need to be surgically removed (a procedure called dista...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07659639 · Fondazione Policlinico Universitario Campus Bio-Medico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇮🇹 IT

Who might be able to join this trial: - People who have not previously been diagnosed with any type of cancer or tumour - People whose kidneys and liver are functioning well enough to meet the trial's health requirements - People who do not have any blood or bone marrow disorders - People who are 18 years of age or old...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07670286 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by laboratory testing of tissue. - People aged 18 or older who have an expected survival time of at least one month, based on a medical assessment of tumour b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07671339 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma), confirmed through laboratory testing of a tissue sample. - People whose tumour has one of seven specific gene changes (mutations) in a gene called KRAS: G12D, G12V, G12R, G12C, G12...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07683845 · Beijing Daxiang Biotech Co., Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any sex - People who have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC), confirmed through laboratory testing of tissue, and who have not yet received any treatment for it - People from...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07692750 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to give written consent and are able to follow the trial schedule and procedures. - People who have been confirmed by tissue testing to have pancreatic cancer that cannot be surgically removed, has come back, or has spread to other parts of the body. - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07703813 · Evangelismos Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 January 2028
🇬🇷 GR

Who might be able to join this trial: - People aged 18 years or older (and no older than 75 years) - People who are scheduled to have surgery to remove all or part of the pancreas due to a pancreatic tumour (this includes procedures known as a Whipple procedure or distal pancreatectomy) - People who are able to have th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07710495 · University of Surrey Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 years or older - People who are planned to have a major surgery called a Whipple's procedure to remove a suspected cancerous growth near where the stomach meets the small intestine - People who are able and willing to sign a consent form agreeing to take part Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Pancreatic Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Two national bodies exist: Pankind, the Australian Pancreatic Cancer Foundation, dedicated specifically to pancreatic cancer, and the Pancare Foundation, which covers pancreatic, liver, biliary, stomach and oesophageal cancers.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.